CA3142030A1 - Compounds useful to treat influenza virus infections - Google Patents
Compounds useful to treat influenza virus infections Download PDFInfo
- Publication number
- CA3142030A1 CA3142030A1 CA3142030A CA3142030A CA3142030A1 CA 3142030 A1 CA3142030 A1 CA 3142030A1 CA 3142030 A CA3142030 A CA 3142030A CA 3142030 A CA3142030 A CA 3142030A CA 3142030 A1 CA3142030 A1 CA 3142030A1
- Authority
- CA
- Canada
- Prior art keywords
- dihydrodibenzo
- compound
- pharmaceutically acceptable
- solvate
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 221
- 241000712461 unidentified influenza virus Species 0.000 title abstract description 33
- 230000009385 viral infection Effects 0.000 title abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims description 115
- 239000012453 solvate Substances 0.000 claims description 82
- -1 methyl methyl carbonate Chemical compound 0.000 claims description 34
- 229910052739 hydrogen Inorganic materials 0.000 claims description 29
- 125000005843 halogen group Chemical group 0.000 claims description 28
- 125000000217 alkyl group Chemical group 0.000 claims description 25
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 24
- ITFBHIXXJXZODU-UHFFFAOYSA-N pyrido[2,1-f][1,2,4]triazine-6,8-dione Chemical compound N=1N2C(C=NC=1)=CC(CC2=O)=O ITFBHIXXJXZODU-UHFFFAOYSA-N 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 20
- 206010022000 influenza Diseases 0.000 claims description 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 17
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 14
- 125000004076 pyridyl group Chemical group 0.000 claims description 14
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 13
- 125000005842 heteroatom Chemical group 0.000 claims description 13
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 10
- 125000001188 haloalkyl group Chemical group 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 6
- JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 claims description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 5
- 229910052698 phosphorus Inorganic materials 0.000 claims description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 4
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- BQIVJVAZDJHDJF-LURJTMIESA-N ethyl (2s)-2-amino-3-methylbutanoate Chemical compound CCOC(=O)[C@@H](N)C(C)C BQIVJVAZDJHDJF-LURJTMIESA-N 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- CEMZBWPSKYISTN-YFKPBYRVSA-N methyl (2s)-2-amino-3-methylbutanoate Chemical compound COC(=O)[C@@H](N)C(C)C CEMZBWPSKYISTN-YFKPBYRVSA-N 0.000 claims description 4
- QVDXUKJJGUSGLS-LURJTMIESA-N methyl L-leucinate Chemical compound COC(=O)[C@@H](N)CC(C)C QVDXUKJJGUSGLS-LURJTMIESA-N 0.000 claims description 4
- RCIJMMSZBQEWKW-UHFFFAOYSA-N methyl propan-2-yl carbonate Chemical compound COC(=O)OC(C)C RCIJMMSZBQEWKW-UHFFFAOYSA-N 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 3
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 abstract description 7
- 230000029812 viral genome replication Effects 0.000 abstract description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 62
- 239000000203 mixture Substances 0.000 description 52
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 43
- 239000000243 solution Substances 0.000 description 38
- 238000006243 chemical reaction Methods 0.000 description 33
- 230000015572 biosynthetic process Effects 0.000 description 30
- 238000003786 synthesis reaction Methods 0.000 description 30
- 239000007787 solid Substances 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 201000010099 disease Diseases 0.000 description 19
- 239000011541 reaction mixture Substances 0.000 description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 125000004432 carbon atom Chemical group C* 0.000 description 17
- 238000001990 intravenous administration Methods 0.000 description 15
- 238000003305 oral gavage Methods 0.000 description 14
- 239000000725 suspension Substances 0.000 description 14
- 230000037396 body weight Effects 0.000 description 13
- 239000011669 selenium Substances 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- FIDLLEYNNRGVFR-CTNGQTDRSA-N (3R)-2-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-11-hydroxy-5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-9,12-dione Chemical compound OC1=C2N(C=CC1=O)N([C@@H]1COCCN1C2=O)[C@@H]1C2=C(SCC3=C1C=CC(F)=C3F)C=CC=C2 FIDLLEYNNRGVFR-CTNGQTDRSA-N 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 208000037797 influenza A Diseases 0.000 description 11
- 208000037798 influenza B Diseases 0.000 description 11
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- 238000002953 preparative HPLC Methods 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 208000037799 influenza C Diseases 0.000 description 10
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- RZVPBGBYGMDSBG-GGAORHGYSA-N baloxavir marboxil Chemical compound COC(=O)OCOc1c2C(=O)N3CCOC[C@H]3N([C@H]3c4ccc(F)c(F)c4CSc4ccccc34)n2ccc1=O RZVPBGBYGMDSBG-GGAORHGYSA-N 0.000 description 9
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 229940008411 baloxavir marboxil Drugs 0.000 description 8
- 239000012267 brine Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- 241000282693 Cercopithecidae Species 0.000 description 7
- 102000004533 Endonucleases Human genes 0.000 description 7
- 108010042407 Endonucleases Proteins 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 229910013470 LiC1 Inorganic materials 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- 235000011152 sodium sulphate Nutrition 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 101150041968 CDC13 gene Proteins 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- 125000001153 fluoro group Chemical group F* 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 238000012453 sprague-dawley rat model Methods 0.000 description 6
- 239000012224 working solution Substances 0.000 description 6
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 239000007832 Na2SO4 Substances 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 5
- 230000002155 anti-virotic effect Effects 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 125000004438 haloalkoxy group Chemical group 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 229960003752 oseltamivir Drugs 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 4
- QBNVDZNXSXEEFL-UHFFFAOYSA-N 3,4-difluoro-2-(phenylselanylmethyl)benzoic acid Chemical compound FC=1C(=C(C(=O)O)C=CC=1F)C[Se]C1=CC=CC=C1 QBNVDZNXSXEEFL-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000282567 Macaca fascicularis Species 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 229960002194 oseltamivir phosphate Drugs 0.000 description 4
- 235000015320 potassium carbonate Nutrition 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000002911 sialidase inhibitor Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010011485 Aspartame Proteins 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 241000233805 Phoenix Species 0.000 description 3
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 3
- 229960003805 amantadine Drugs 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 239000000605 aspartame Substances 0.000 description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 3
- 235000010357 aspartame Nutrition 0.000 description 3
- 229960003438 aspartame Drugs 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 229940125810 compound 20 Drugs 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 210000004731 jugular vein Anatomy 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 3
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 229960000888 rimantadine Drugs 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- XASWYPVFCVEQSU-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;potassium Chemical compound [K].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O XASWYPVFCVEQSU-UHFFFAOYSA-N 0.000 description 2
- UOYAGLRGMZBIKY-UHFFFAOYSA-N 4,5-difluoro-3-hydroxy-3H-2-benzofuran-1-one Chemical compound OC1OC(=O)c2ccc(F)c(F)c12 UOYAGLRGMZBIKY-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229920002148 Gellan gum Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- QNRRHYPPQFELSF-CNYIRLTGSA-N Laninamivir Chemical compound OC[C@@H](O)[C@@H](OC)[C@@H]1OC(C(O)=O)=C[C@H](N=C(N)N)[C@H]1NC(C)=O QNRRHYPPQFELSF-CNYIRLTGSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000238367 Mya arenaria Species 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical class C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 229940121357 antivirals Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- WQAWEUZTDVWTDB-UHFFFAOYSA-N dimethyl(oxo)phosphanium Chemical compound C[P+](C)=O WQAWEUZTDVWTDB-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 235000010492 gellan gum Nutrition 0.000 description 2
- 239000000216 gellan gum Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 229940126181 ion channel inhibitor Drugs 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 229950004244 laninamivir Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000001853 liver microsome Anatomy 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000003228 microsomal effect Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 229960001084 peramivir Drugs 0.000 description 2
- UGTYTOKVOXBJBZ-LINPMSLLSA-N peramivir hydrate Chemical compound O.O.O.O.CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N UGTYTOKVOXBJBZ-LINPMSLLSA-N 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- 229960001028 zanamivir Drugs 0.000 description 2
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- TWYYFYNJOJGNFP-CUXYNZQBSA-N (2s,4r,5s,6s)-2-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-2-carbamoyl-4-[[(e,4s,6s)-4,6-dimethyloct-2-enoyl]oxymethyl]-5-hydroxy-1,3-dioxane-4,5,6-tricarboxylic acid Chemical compound O1[C@H](C(O)=O)[C@](C(O)=O)(O)[C@](COC(=O)/C=C/[C@@H](C)C[C@@H](C)CC)(C(O)=O)O[C@]1(C(N)=O)CCC(=C)[C@@H](OC(C)=O)[C@H](C)CC1=CC=CC=C1 TWYYFYNJOJGNFP-CUXYNZQBSA-N 0.000 description 1
- 125000006677 (C1-C3) haloalkoxy group Chemical group 0.000 description 1
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 description 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- DYNFCHNNOHNJFG-UHFFFAOYSA-N 2-formylbenzoic acid Chemical class OC(=O)C1=CC=CC=C1C=O DYNFCHNNOHNJFG-UHFFFAOYSA-N 0.000 description 1
- FPENCTDAQQQKNY-UHFFFAOYSA-N 3,4-difluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C(F)=C1 FPENCTDAQQQKNY-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OBEXFUFBCNVOKB-UHFFFAOYSA-N 7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-ol Chemical compound OC1c2ccccc2SCc2c(F)c(F)ccc12 OBEXFUFBCNVOKB-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 229940124947 FluMist Quadrivalent Drugs 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 206010022005 Influenza viral infections Diseases 0.000 description 1
- 101710199769 Matrix protein 2 Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229940123066 Polymerase inhibitor Drugs 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- HDYANYHVCAPMJV-LXQIFKJMSA-N UDP-alpha-D-glucuronic acid Chemical compound C([C@@H]1[C@H]([C@H]([C@@H](O1)N1C(NC(=O)C=C1)=O)O)O)OP(O)(=O)OP(O)(=O)O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O HDYANYHVCAPMJV-LXQIFKJMSA-N 0.000 description 1
- HDYANYHVCAPMJV-UHFFFAOYSA-N Uridine diphospho-D-glucuronic acid Natural products O1C(N2C(NC(=O)C=C2)=O)C(O)C(O)C1COP(O)(=O)OP(O)(=O)OC1OC(C(O)=O)C(O)C(O)C1O HDYANYHVCAPMJV-UHFFFAOYSA-N 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- CTPOHARTNNSRSR-APJZLKAGSA-N beraprost Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC(O)=O CTPOHARTNNSRSR-APJZLKAGSA-N 0.000 description 1
- 229960002890 beraprost Drugs 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical group C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- MFSHZGFPADYOTO-UHFFFAOYSA-N chloromethyl methyl carbonate Chemical compound COC(=O)OCCl MFSHZGFPADYOTO-UHFFFAOYSA-N 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011340 continuous therapy Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- YVXVNGVYXSQARS-UHFFFAOYSA-N diethyl(oxo)phosphanium Chemical compound CC[P+](=O)CC YVXVNGVYXSQARS-UHFFFAOYSA-N 0.000 description 1
- 125000004982 dihaloalkyl group Chemical group 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 description 1
- 229950008454 favipiravir Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000009459 flexible packaging Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000021471 food effect Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- UKTIJASCFRNWCB-RMIBSVFLSA-N laninamivir octanoate hydrate Chemical compound CCCCCCCC(=O)OC[C@@H](O)[C@@H](OC)[C@@H]1OC(C(O)=O)=C[C@H](N=C(N)N)[C@H]1NC(C)=O UKTIJASCFRNWCB-RMIBSVFLSA-N 0.000 description 1
- 229950005327 laninamivir octanoate hydrate Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229910052760 oxygen Chemical group 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 150000003077 polyols Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 102200015461 rs28936072 Human genes 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007905 soft elastic gelatin capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000007444 viral RNA synthesis Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
The invention provides compounds that may inhibit influenza virus replication, and are accordingly useful for treatment of viral infections caused by influenza virus. The invention further provides pharmaceutical compositions containing these compounds and methods of using these compounds to treat or prevent viral infections caused by influenza virus.
Description
COMPOUNDS USEFUL TO TREAT INFLUENZA VIRUS INFECTIONS
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims prior benefit of U.S. Provisional Patent Application No.
62/872,998, filed July 11,2019, and of U.S. Provisional Patent Application No.
62/944,309, filed December 5, 2019, the disclosures of each of which are hereby incorporated herein by reference in their entirety FIELD OF THE INVENTION
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims prior benefit of U.S. Provisional Patent Application No.
62/872,998, filed July 11,2019, and of U.S. Provisional Patent Application No.
62/944,309, filed December 5, 2019, the disclosures of each of which are hereby incorporated herein by reference in their entirety FIELD OF THE INVENTION
[0002] This disclosure relates generally to compounds and compositions that may be useful for treatment of viral infections.
BACKGROUND
BACKGROUND
[0003] Influenza occurs in annual outbreaks each fall and winter worldwide.
Influenza typically causes a self-limited respiratory illness with fever that lasts from 3 to 7 days. In spite of the availability of influenza vaccines, across the globe, there are an estimated 1 billion cases of influenza, 3-5 million are severe cases and 290000-650000 lead to influenza-related respiratory deaths each year (WHO: Global Influenza Strategy and Iuliano AD et al. Lancet. 2018, 391, 1285-300).
Influenza typically causes a self-limited respiratory illness with fever that lasts from 3 to 7 days. In spite of the availability of influenza vaccines, across the globe, there are an estimated 1 billion cases of influenza, 3-5 million are severe cases and 290000-650000 lead to influenza-related respiratory deaths each year (WHO: Global Influenza Strategy and Iuliano AD et al. Lancet. 2018, 391, 1285-300).
[0004] Influenza viruses belong to the family Or thomyxovir idae , which are enveloped viruses containing a single-stranded, negative-sense RNA genome. Two classes of anti-Influenza viruses therapies, M2 ion-channel inhibitors and neuraminidase inhibitors, are commonly available in the past decades. However, resistance to M2 ion-channel inhibitors has been widely observed, and the emergence of antiviral resistance to neuraminidase inhibitors remains a threat. Matrix Protein 2 (M2) Inhibitors, Rimantadine and Amantadine, inhibit influenza A virus replication by occluding the M2 proton channel, but lack activity against influenza B virus (Gu R, Liu LA, Wei D, Trends Pharmacol Sci 2013, 34, 571).
[0005] Additional effective antiviral agents are needed for the treatment and prevention of influenza virus infections. Influenza viral RNA - dependent RNA polymerase (RdRp) with endonuclease activity cleaves a section of the capped 5'-end of cellular mRNA
and use them to prime transcription of viral mRNA, the process known as "cap-snatching". A
ribonucleoprotein complex composed of PA, PB1 and PB2 subunits, is responsible and essential for the "cap-snatching" process. The influenza virus polymerase complex has received considerable attention as a target to small molecule inhibitors for the treatment of
and use them to prime transcription of viral mRNA, the process known as "cap-snatching". A
ribonucleoprotein complex composed of PA, PB1 and PB2 subunits, is responsible and essential for the "cap-snatching" process. The influenza virus polymerase complex has received considerable attention as a target to small molecule inhibitors for the treatment of
6 influenza virus infection (Stevaert, A. & Naesens, L, Medicinal Research Reviews 2016, 36, 1127-1173). In 2018, baloxavir marboxil (Xofluza), a cap-dependent endonuclease (CEN) inhibitor, was approved in the US and Japan for treatment of influenza A and influenza B.
Baloxavir marboxil is a prodrug that is converted through hydrolysis to its active form, baloxavir. Baloxavir inhibits influenza virus polymerase acidic (PA) protein endonuclease resulting in inhibition of viral RNA synthesis. However, in 2.2% of recipients in the phase 2 trial and in about 10% of recipients in the phase 3 trial, the influenza strain became resistant, which was due to I38T/M/F mutants (Shinya 0 et al., Scientific Reports 2018, 8, 9633).
Furthermore, baloxavir marboxil and its active component baloxavir have poor oral availability.
[0006] Therefore, there is an urgent need to develop new therapeutics that have improved pharmaceutical and/or biological properties.
BRIEF DESCRIPTION OF THE FIGURES
Baloxavir marboxil is a prodrug that is converted through hydrolysis to its active form, baloxavir. Baloxavir inhibits influenza virus polymerase acidic (PA) protein endonuclease resulting in inhibition of viral RNA synthesis. However, in 2.2% of recipients in the phase 2 trial and in about 10% of recipients in the phase 3 trial, the influenza strain became resistant, which was due to I38T/M/F mutants (Shinya 0 et al., Scientific Reports 2018, 8, 9633).
Furthermore, baloxavir marboxil and its active component baloxavir have poor oral availability.
[0006] Therefore, there is an urgent need to develop new therapeutics that have improved pharmaceutical and/or biological properties.
BRIEF DESCRIPTION OF THE FIGURES
[0007] Figure 1A and Figure 1B illustrate antivirus efficacy in influenza virus PR/8/34 mouse model. Figure 1A shows the body weight change and Figure 1B shows the percent survival, when Compound B-1, Compound C-1, Oseltamivir Phosphate or vehicle was administered.
SUMMARY OF THE INVENTION
SUMMARY OF THE INVENTION
[0008] In one aspect, provided is a compound of Formula (I):
G, 0 0 (R4)P
N
N,NO
k --(ROrn or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein Ri, R2, R3, R4, m, n, p, and G are as detailed herein.
G, 0 0 (R4)P
N
N,NO
k --(ROrn or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein Ri, R2, R3, R4, m, n, p, and G are as detailed herein.
[0009] In one aspect, provided is a compound of Formula (II):
G.
0 0 (R4)P
N
R3 N ,N
x /
(Ri)n (II), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein Ri, R2, R3, R4, m, n, p, and G are as detailed herein.
G.
0 0 (R4)P
N
R3 N ,N
x /
(Ri)n (II), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein Ri, R2, R3, R4, m, n, p, and G are as detailed herein.
[0010] In some embodiments, the compound of Formula (I) or (II), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, is of Formula (I-1), (I-2), (I-3), (II-1), (II-2), or (II-3), as detailed herein.
[0011] In another aspect, provided is a method of treating or preventing influenza virus infections.
[0012] In some embodiments, provided is a method of treating influenza, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or (II), or pharmaceutically acceptable salt, stereoisomer or solvate thereof
[0013] Also provided are pharmaceutical compositions comprising: (A) a compound detailed herein, such as a compound of Formula (I) or (II), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof; and (B) a pharmaceutically acceptable carrier or excipient. Kits comprising a compound detailed herein or a pharmaceutically acceptable salt, stereoisomer or solvate thereof and optionally instructions for use are also provided.
[0014] Compounds as detailed herein or a pharmaceutically acceptable salt, stereoisomer or solvate thereof are provided for use as a medicament. Compounds as detailed herein or a pharmaceutically acceptable salt, stereoisomer or solvate thereof are also provided for the manufacture of a medicament for the treatment or prevention of influenza virus infections.
[0015] Compounds as detailed herein or a pharmaceutically acceptable salt, stereoisomer or solvate thereof show superior pharmacokinetic properties and biological activities. For example, there is no food effect to pharmacokinetic parameters in cynomolgus monkeys: oral bioavailabilities of fasted and fed monkey are both more than 50%. Therefore, compounds as detailed herein or a pharmaceutically acceptable salt, stereoisomer or solvate thereof show great advantages.
DETAILED DESCRIPTION
Definitions
DETAILED DESCRIPTION
Definitions
[0016] For use herein, unless clearly indicated otherwise, use of the terms "a", "an" and the like refers to one or more.
[0017] As used herein, and unless otherwise specified, the terms "about" and "approximately," when used in connection with doses, amounts, or weight percent of ingredients of a composition or a dosage form, mean a dose, amount, or weight percent that is recognized by those of ordinary skill in the art to provide a pharmacological effect equivalent to that obtained from the specified dose, amount, or weight percent.
Specifically, the terms "about" and "approximately," when used in connection with a value, contemplate a variation within 15%, within 10%, within 5%, within 4%, within 3%, within 2%, within 1%, or within 0.5% of the specified value. Reference to "about" a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se. For example, description referring to "about X" includes description of "X".
Specifically, the terms "about" and "approximately," when used in connection with a value, contemplate a variation within 15%, within 10%, within 5%, within 4%, within 3%, within 2%, within 1%, or within 0.5% of the specified value. Reference to "about" a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se. For example, description referring to "about X" includes description of "X".
[0018] "Alkyl" as used herein refers to and includes, unless otherwise stated, a saturated linear (i.e., unbranched) or branched univalent hydrocarbon chain or combination thereof, having the number of carbon atoms designated (i.e., Ci-Cio means one to ten carbon atoms).
Particular alkyl groups are those having 1 to 20 carbon atoms (a "Ci-C2o alkyl"), having 1 to carbon atoms (a "Ci-Cio alkyl"), having 6 to 10 carbon atoms (a "C6-Cio alkyl"), having 1 to 6 carbon atoms (a "Ci-C6 alkyl"), having 2 to 6 carbon atoms (a "C2-C6 alkyl"), or having 1 to 4 carbon atoms (a "Ci-C4 alkyl"). Examples of alkyl groups include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, and the like.
Particular alkyl groups are those having 1 to 20 carbon atoms (a "Ci-C2o alkyl"), having 1 to carbon atoms (a "Ci-Cio alkyl"), having 6 to 10 carbon atoms (a "C6-Cio alkyl"), having 1 to 6 carbon atoms (a "Ci-C6 alkyl"), having 2 to 6 carbon atoms (a "C2-C6 alkyl"), or having 1 to 4 carbon atoms (a "Ci-C4 alkyl"). Examples of alkyl groups include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, and the like.
[0019] "Cycloalkyl" as used herein refers to and includes, unless otherwise stated, saturated cyclic univalent hydrocarbon structures, having the number of carbon atoms designated (i.e., C3-Cio means three to ten carbon atoms). Cycloalkyl can consist of one ring, such as cyclohexyl, or multiple rings, such as adamantyl. A cycloalkyl comprising more than one ring may be fused, spiro or bridged, or combinations thereof Particular cycloalkyl groups are those having from 3 to 12 annular carbon atoms. A preferred cycloalkyl is a cyclic hydrocarbon having from 3 to 8 annular carbon atoms (a "C3-C8 cycloalkyl"), having 3 to 6 carbon atoms (a "C3-C6 cycloalkyl"), or having from 3 to 4 annular carbon atoms (a "C3-C4 cycloalkyl"). Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, and the like.
[0020] "Heterocycle" or "heterocyclic" or "heterocycloalkyl" or "heterocycly1"
refers to a saturated or partially saturated, but not aromatic, group having from 1 to 10 ring carbon atoms, preferably from 1 to 8 carbon atoms, and more preferably from 1 to 6 carbon atoms, and from 1 to 4 ring heteroatoms, preferably from 1 to 3 heteroatoms, and more preferably from 1 to 2 heteroatoms selected from the group consisting of nitrogen, sulfur, or oxygen.
Heterocycle encompasses single ring or multiple condensed rings, including fused bridged and spiro ring systems. In fused ring systems, one or more the rings can be cycloalkyl, aryl or heteroaryl provided that the point of attachment is through the non-aromatic ring. In one embodiment, the nitrogen and/or sulfur atom(s) of the heterocyclic group are optionally oxidized to provide for the N-oxide, sulfinyl, sulfonyl moieties.
refers to a saturated or partially saturated, but not aromatic, group having from 1 to 10 ring carbon atoms, preferably from 1 to 8 carbon atoms, and more preferably from 1 to 6 carbon atoms, and from 1 to 4 ring heteroatoms, preferably from 1 to 3 heteroatoms, and more preferably from 1 to 2 heteroatoms selected from the group consisting of nitrogen, sulfur, or oxygen.
Heterocycle encompasses single ring or multiple condensed rings, including fused bridged and spiro ring systems. In fused ring systems, one or more the rings can be cycloalkyl, aryl or heteroaryl provided that the point of attachment is through the non-aromatic ring. In one embodiment, the nitrogen and/or sulfur atom(s) of the heterocyclic group are optionally oxidized to provide for the N-oxide, sulfinyl, sulfonyl moieties.
[0021] "Halo" or "halogen" refers to elements of the Group 17 series having atomic number 9 to 85. Preferred halo groups include the radicals of fluorine, chlorine, bromine and iodine. Where a residue is substituted with more than one halogen, it may be referred to by using a prefix corresponding to the number of halogen moieties attached, e.g., dihaloaryl, dihaloalkyl, trihaloaryl etc. refer to aryl and alkyl substituted with two ("di") or three ("tri") halo groups, which may be but are not necessarily the same halogen; thus 4-chloro-3-fluorophenyl is within the scope of dihaloaryl. An alkyl group in which each hydrogen is replaced with a halo group is referred to as a "perhaloalkyl." A preferred perhaloalkyl group is trifluoromethyl (-CF3).
[0022] "Pharmaceutically acceptable salts" are those salts which retain at least some of the biological activity of the free (non-salt) compound and which can be administered as drugs or pharmaceuticals to an individual. Such salts, for example, include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, oxalic acid, propionic acid, succinic acid, maleic acid, tartaric acid and the like;
(2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base. Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine and the like. Acceptable inorganic bases which can be used to prepared salts include aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like. Pharmaceutically acceptable salts can be prepared in situ in the manufacturing process, or by separately reacting a purified compound of the invention in its free acid or base form with a suitable organic or inorganic base or acid, respectively, and isolating the salt thus formed during subsequent purification.
(2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base. Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine and the like. Acceptable inorganic bases which can be used to prepared salts include aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like. Pharmaceutically acceptable salts can be prepared in situ in the manufacturing process, or by separately reacting a purified compound of the invention in its free acid or base form with a suitable organic or inorganic base or acid, respectively, and isolating the salt thus formed during subsequent purification.
[0023] A "pharmaceutically acceptable carrier" refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, which is nontoxic to a subject.
A
pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.
A
pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.
[0024] The term "excipient" as used herein means an inert or inactive substance that may be used in the production of a drug or pharmaceutical, such as a tablet containing a compound of the invention as an active ingredient. Various substances may be embraced by the term excipient, including without limitation any substance used as a binder, disintegrant, coating, compression/encapsulation aid, cream or lotion, lubricant, solutions for parenteral administration, materials for chewable tablets, sweetener or flavoring, suspending/gelling agent, or wet granulation agent. Binders include, e.g., carbomers, povidone, xanthan gum, etc.; coatings include, e.g., cellulose acetate phthalate, ethylcellulose, gellan gum, maltodextrin, enteric coatings, etc.; compression/encapsulation aids include, e.g., calcium carbonate, dextrose, fructose dc (dc = "directly compressible"), honey dc, lactose (anhydrate or monohydrate; optionally in combination with aspartame, cellulose, or microcrystalline cellulose), starch dc, sucrose, etc.; disintegrants include, e.g., croscarmellose sodium, gellan gum, sodium starch glycolate, etc.; creams or lotions include, e.g., maltodextrin, carrageenans, etc.; lubricants include, e.g., magnesium stearate, stearic acid, sodium stearyl fumarate, etc.; materials for chewable tablets include, e.g., dextrose, fructose dc, lactose (monohydrate, optionally in combination with aspartame or cellulose), etc.;
suspending/gelling agents include, e.g., carrageenan, sodium starch glycolate, xanthan gum, etc.; sweeteners include, e.g., aspartame, dextrose, fructose dc, sorbitol, sucrose dc, etc.; and wet granulation agents include, e.g., calcium carbonate, maltodextrin, microcrystalline cellulose, etc.
suspending/gelling agents include, e.g., carrageenan, sodium starch glycolate, xanthan gum, etc.; sweeteners include, e.g., aspartame, dextrose, fructose dc, sorbitol, sucrose dc, etc.; and wet granulation agents include, e.g., calcium carbonate, maltodextrin, microcrystalline cellulose, etc.
[0025] "Stereoisomer" or "stereoisomers" refer to compounds that differ in the stereogenicity of the constituent atoms such as, without limitation, in the chirality of one or more stereocenters or related to the cis or trans configuration of a carbon-carbon or carbon-nitrogen double bond. Stereoisomers include enantiomers and diastereomers.
[0026] As used herein, "treatment" or "treating" is an approach for obtaining beneficial or desired results including clinical results. For example, beneficial or desired results include, but are not limited to, one or more of the following: decreasing symptoms resulting from the disease, increasing the quality of life of those suffering from the disease, decreasing the dose of other medications required to treat the disease, delaying the progression of the disease, and/or prolonging survival of an individual.
[0027] As used herein, an "effective dosage" or "effective amount" of compound or salt thereof or pharmaceutical composition is an amount sufficient to effect beneficial or desired results. For prophylactic use, beneficial or desired results include results such as eliminating or reducing the risk, lessening the severity of, or delaying the onset of the disease, including biochemical, histological and/or behavioral symptoms of the disease, its complications and intermediate pathological phenotypes presenting during development of the disease. For therapeutic use, beneficial or desired results include ameliorating, palliating, lessening, delaying or decreasing one or more symptoms resulting from the disease, increasing the quality of life of those suffering from the disease, decreasing the dose of other medications required to treat the disease, enhancing effect of another medication such as via targeting, delaying the progression of the disease, and/or prolonging survival. In some embodiments, an effective amount is an amount sufficient to delay development. In some embodiments, an effective amount is an amount sufficient to prevent or delay recurrence. An effective dosage can be administered in one or more administrations. For purposes of this disclosure, an effective dosage of compound or a salt thereof, or pharmaceutical composition is an amount sufficient to accomplish prophylactic or therapeutic treatment either directly or indirectly. It is intended and understood that an effective dosage of a compound or salt thereof, or pharmaceutical composition may or may not be achieved in conjunction with another drug, compound, or pharmaceutical composition. Thus, an "effective dosage" may be considered in the context of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desirable result may be or is achieved.
[0028] As used herein, the term "subject" is a mammal, including humans. A
subject includes, but is not limited to, human, bovine, horse, feline, canine, rodent, or primate. In some embodiments, the subject is human.
subject includes, but is not limited to, human, bovine, horse, feline, canine, rodent, or primate. In some embodiments, the subject is human.
[0029] Unless otherwise stated, "substantially pure" intends a composition that contains no more than 10% impurity, such as a composition comprising less than about 9%, 7%, 5%, 3%, 1%, 0.5% impurity.
[0030] It is understood that aspects and variations described herein also include "consisting" and/or "consisting essentially of" aspects and variations.
[0031] All references throughout, such as publications, patents, patent applications and published patent applications, are incorporated herein by reference in their entireties.
Compounds
Compounds
[0032] In one aspect, the invention provides a compound of Formula (I):
G..0 0 (R4)P
0)YL N
R3 N .N
(Ri)n%. /
Se (I), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein:
each Ri is independently selected from the group consisting of H and halo;
each R2 is independently selected from the group consisting of H and halo;
R3 is selected from the group consisting of H, halo, Me, CN, and P(0)Me2;
each R4 is independently selected from the group consisting of C1-C6 alkyl and cycloalkyl, wherein any two of R4 are optionally taken, together with the atoms to which they are attached, to form a C3-C6 cycloalkyl;
n and m are each independently 0, 1, 2, 3, or 4;
p is 0, 1, 2, or 3; and G is H or is selected from the group consisting of C(0)R, C(0)0R, C(0)NR'R, C(102-0-C(0)R, C(102-0-C(0)0R, and C(R')2-0-C(0)NR'R, wherein each R is selected from the group consisting of Ci-C6 alkyl, phenyl, pyridyl, cycloalkyl, and a 4-6 membered heterocyclic ring containing one or two heteroatoms selected from the group consisting of N, 0 and S as ring members, wherein the Ci-C6 alkyl, phenyl, pyridyl, C3-C6 cycloalkyl, and 4-6 membered heterocyclic ring of R are independently optionally substituted with one or two substituents selected from the group consisting of H, halo, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-haloalkoxy; and each R' is independently selected from the group consisting of H and C1-C3 alkyl.
G..0 0 (R4)P
0)YL N
R3 N .N
(Ri)n%. /
Se (I), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein:
each Ri is independently selected from the group consisting of H and halo;
each R2 is independently selected from the group consisting of H and halo;
R3 is selected from the group consisting of H, halo, Me, CN, and P(0)Me2;
each R4 is independently selected from the group consisting of C1-C6 alkyl and cycloalkyl, wherein any two of R4 are optionally taken, together with the atoms to which they are attached, to form a C3-C6 cycloalkyl;
n and m are each independently 0, 1, 2, 3, or 4;
p is 0, 1, 2, or 3; and G is H or is selected from the group consisting of C(0)R, C(0)0R, C(0)NR'R, C(102-0-C(0)R, C(102-0-C(0)0R, and C(R')2-0-C(0)NR'R, wherein each R is selected from the group consisting of Ci-C6 alkyl, phenyl, pyridyl, cycloalkyl, and a 4-6 membered heterocyclic ring containing one or two heteroatoms selected from the group consisting of N, 0 and S as ring members, wherein the Ci-C6 alkyl, phenyl, pyridyl, C3-C6 cycloalkyl, and 4-6 membered heterocyclic ring of R are independently optionally substituted with one or two substituents selected from the group consisting of H, halo, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-haloalkoxy; and each R' is independently selected from the group consisting of H and C1-C3 alkyl.
[0033] In some embodiments, provided is a compound of Formula (I-1):
G, 0)y= N
N
(R2)m (Ri)n or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein Ri, R2, R3, R4, m, n, p, and G are as detailed herein for Formula (I).
G, 0)y= N
N
(R2)m (Ri)n or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein Ri, R2, R3, R4, m, n, p, and G are as detailed herein for Formula (I).
[0034] In some embodiments, provided is a compound of Formula (I-2):
G, *.LN
(Ri)n Se (I-2), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein Ri, n, and G
are as detailed herein for Formula (I).
G, *.LN
(Ri)n Se (I-2), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein Ri, n, and G
are as detailed herein for Formula (I).
[0035] In some embodiments, provides is a compound selected from the group consisting of:
G0 , G,0 G.
otYLN o*LNI o*.L N
F - _ --F
Se Se F Se F
G. .
G, 0 G0 0 0 o*LN c)*(N o)Y(N
N.N 0 N.N)NNe0 N.N).0 F -F -F
Se Se Se G, 0 0 G, G, o*LN
N.N 0 N.N 0 F -: F F
F
Se F Se Se F , or a pharmaceutically acceptable salt, stereoisomer or solvate thereof
G0 , G,0 G.
otYLN o*LNI o*.L N
F - _ --F
Se Se F Se F
G. .
G, 0 G0 0 0 o*LN c)*(N o)Y(N
N.N 0 N.N)NNe0 N.N).0 F -F -F
Se Se Se G, 0 0 G, G, o*LN
N.N 0 N.N 0 F -: F F
F
Se F Se Se F , or a pharmaceutically acceptable salt, stereoisomer or solvate thereof
[0036] In some embodiments, provided is a compound of Formula (I-3):
G.
o)YN
N.N),N4.0 -E
F
Se F (I-3), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein G is as detailed herein for Formula (I).
G.
o)YN
N.N),N4.0 -E
F
Se F (I-3), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein G is as detailed herein for Formula (I).
[0037] In another aspect, the invention provides a compound of Formula (II):
G, 0 0 (R4)P
0*LN 1 , )0 (ROM
X
or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein:
each Ri is independently selected from the group consisting of H and halo;
each R2 is independently selected from the group consisting of H and halo;
R3 is P(0)Me2 or P(0)Et2;
each R4 is independently selected from the group consisting of C1-C6 alkyl and cycloalkyl, wherein any two of R4 are optionally taken, together with the atoms to which they are attached, to form a C3-C6 cycloalkyl;
n and m are each independently 0, 1, 2, 3, or 4;
p is 0, 1, 2, or 3; and G is H or is selected from the group consisting of C(0)R, C(0)0R, C(0)NR'R, C(102-0-C(0)R, C(102-0-C(0)0R, and C(R')2-0-C(0)NR'R, wherein each R is selected from the group consisting of C1-C6 alkyl, phenyl, pyridyl, cycloalkyl, and a 4-6 membered heterocyclic ring containing one or two heteroatoms selected from the group consisting of N, 0 and S as ring members, wherein the C1-C6 alkyl, phenyl, pyridyl, C3-C6 cycloalkyl, and 4-6 membered heterocyclic ring of R are independently optionally substituted with one or two substituents selected from the group consisting of H, halo, CN, OH, NH2, Ci-C3 alkyl, phenyl, Ci-C4 alkoxy, Ci-C3 haloalkyl, and Ci-haloalkoxy; and each R' is independently selected from the group consisting of H and Ci-C3 alkyl.
G, 0 0 (R4)P
0*LN 1 , )0 (ROM
X
or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein:
each Ri is independently selected from the group consisting of H and halo;
each R2 is independently selected from the group consisting of H and halo;
R3 is P(0)Me2 or P(0)Et2;
each R4 is independently selected from the group consisting of C1-C6 alkyl and cycloalkyl, wherein any two of R4 are optionally taken, together with the atoms to which they are attached, to form a C3-C6 cycloalkyl;
n and m are each independently 0, 1, 2, 3, or 4;
p is 0, 1, 2, or 3; and G is H or is selected from the group consisting of C(0)R, C(0)0R, C(0)NR'R, C(102-0-C(0)R, C(102-0-C(0)0R, and C(R')2-0-C(0)NR'R, wherein each R is selected from the group consisting of C1-C6 alkyl, phenyl, pyridyl, cycloalkyl, and a 4-6 membered heterocyclic ring containing one or two heteroatoms selected from the group consisting of N, 0 and S as ring members, wherein the C1-C6 alkyl, phenyl, pyridyl, C3-C6 cycloalkyl, and 4-6 membered heterocyclic ring of R are independently optionally substituted with one or two substituents selected from the group consisting of H, halo, CN, OH, NH2, Ci-C3 alkyl, phenyl, Ci-C4 alkoxy, Ci-C3 haloalkyl, and Ci-haloalkoxy; and each R' is independently selected from the group consisting of H and Ci-C3 alkyl.
[0038] In some embodiments, provided is a compound of Formula (II-1):
G.
0 0 (R4)P
0)yLNVI
r.c3 X / /
G.
0 0 (R4)P
0)yLNVI
r.c3 X / /
[0039] or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein Ri, R2, R3, R4, m, n, p, and G are as detailed herein for Formula (II).
[0040] In some embodiments, provided is a compound of Formula (II-2):
G.
rN3 (Ri)nX /
(II-2), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein Ri, n, R3 and G are as detailed herein for Formula (II).
G.
rN3 (Ri)nX /
(II-2), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein Ri, n, R3 and G are as detailed herein for Formula (II).
[0041] In some embodiments, provided is a compound of Formula (II-3):
G..0 0 llN
rk N.N),NO
(II-3), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein R3 and G are as detailed herein for Formula (II).
G..0 0 llN
rk N.N),NO
(II-3), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein R3 and G are as detailed herein for Formula (II).
[0042] In some embodiments, the invention provides a compound of Formula (I), (I-1), (I-2), (I-3), (II), (II-1), (II-2), or (II-3), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein G is hydrogen or is selected from the group consisting of:
=0y0 yy0 e0y0 1101.r e0y0 l'r0y0 410y0e 0 0 0 0 , 0 , syy00 Ce0y0 y \13 sr C\0 41,0y0,00 =r0y0,00 0_0 =, 0 0 0 e) =r0Irc =,(DyC
=() =õ0y, ,and=
Pharmaceutical Compositions and Formulations
=0y0 yy0 e0y0 1101.r e0y0 l'r0y0 410y0e 0 0 0 0 , 0 , syy00 Ce0y0 y \13 sr C\0 41,0y0,00 =r0y0,00 0_0 =, 0 0 0 e) =r0Irc =,(DyC
=() =õ0y, ,and=
Pharmaceutical Compositions and Formulations
[0043] Pharmaceutical compositions of any of the compounds detailed herein or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, are embraced by this disclosure. Thus, the present disclosure includes pharmaceutical compositions comprising a compound as detailed herein or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, and a pharmaceutically acceptable carrier or excipient. In one aspect, the pharmaceutically acceptable salt is an acid addition salt, such as a salt formed with an inorganic or organic acid. Pharmaceutical compositions may take a form suitable for oral, buccal, parenteral, nasal, topical or rectal administration or a form suitable for administration by inhalation.
[0044] A compound as detailed herein or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, may in one aspect be in a purified form and compositions comprising a compound in purified forms are detailed herein. Compositions comprising a compound as detailed herein or a salt thereof are provided, such as compositions of substantially pure compounds. In some embodiments, a composition containing a compound as detailed herein or a salt thereof is in substantially pure form.
[0045] In one variation, the compounds herein are synthetic compounds prepared for administration to an individual. In another variation, compositions are provided containing a compound in substantially pure form. In another variation, the present disclosure embraces pharmaceutical compositions comprising a compound detailed herein or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, and a pharmaceutically acceptable carrier. In another variation, methods of administering a compound are provided. The purified forms, pharmaceutical compositions and methods of administering the compounds are suitable for any compound or form thereof detailed herein.
[0046] A compound detailed herein or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, may be formulated for any available delivery route, including an oral, mucosal (e.g., nasal, sublingual, vaginal, buccal or rectal), parenteral (e.g., intramuscular, subcutaneous or intravenous), topical or transdermal delivery form. A compound or salt thereof may be formulated with suitable carriers to provide delivery forms that include, but are not limited to, tablets, caplets, capsules (such as hard gelatin capsules or soft elastic gelatin capsules), cachets, troches, lozenges, gums, dispersions, suppositories, ointments, cataplasms (poultices), pastes, powders, dressings, creams, solutions, patches, aerosols (e.g., nasal spray or inhalers), gels, suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions or water-in-oil liquid emulsions), solutions and elixirs.
[0047] One or several compounds described herein or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, can be used in the preparation of a formulation, such as a pharmaceutical formulation, by combining the compound or compounds, or a salt thereof, as an active ingredient with a pharmaceutically acceptable carrier, such as those mentioned above. Depending on the therapeutic form of the system (e.g., transdermal patch vs. oral tablet), the carrier may be in various forms. In addition, pharmaceutical formulations may contain preservatives, solubilizers, stabilizers, re-wetting agents, emulgators, sweeteners, dyes, adjusters, and salts for the adjustment of osmotic pressure, buffers, coating agents or antioxidants. Formulations comprising the compound may also contain other substances which have valuable therapeutic properties. Pharmaceutical formulations may be prepared by known pharmaceutical methods. Suitable formulations can be found, e.g., in Remington 's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, PA, 20th ed.
(2000), which is incorporated herein by reference.
(2000), which is incorporated herein by reference.
[0048] Compounds or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, as described herein may be administered to individuals in a form of generally accepted oral compositions, such as tablets, coated tablets, and gel capsules in a hard or in soft shell, emulsions or suspensions. Examples of carriers, which may be used for the preparation of such compositions, are lactose, corn starch or its derivatives, talc, stearate or its salts, etc.
Acceptable carriers for gel capsules with soft shell are, for instance, plant oils, wax, fats, semisolid and liquid poly-ols, and so on. In addition, pharmaceutical formulations may contain preservatives, solubilizers, stabilizers, re-wetting agents, emulgators, sweeteners, dyes, adjusters, and salts for the adjustment of osmotic pressure, buffers, coating agents or antioxidants.
Acceptable carriers for gel capsules with soft shell are, for instance, plant oils, wax, fats, semisolid and liquid poly-ols, and so on. In addition, pharmaceutical formulations may contain preservatives, solubilizers, stabilizers, re-wetting agents, emulgators, sweeteners, dyes, adjusters, and salts for the adjustment of osmotic pressure, buffers, coating agents or antioxidants.
[0049] Any of the compounds described herein or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, can be formulated in a tablet in any dosage form described, for example, a compound as described herein or a pharmaceutically acceptable salt thereof can be formulated as a 10 mg tablet.
Methods of Use and Uses
Methods of Use and Uses
[0050] In addition to the compounds as disclosed herein, their pharmaceutically acceptable salts, stereoisomers, hydrates, solvates, and compositions and combinations comprising these compounds, the invention includes methods of using the same as further described herein.
[0051] The compounds of Formula (I) and (II), including all formulae (I-1), (I-2), (I-3), (II-1), (II-2), and (II-3), are inhibitors of the endonuclease function of influenza viruses as shown by the data provided herein, and they inhibit replication of influenza viruses. Accordingly, these compounds are useful to treat or prevent influenza virus infections in humans.
[0052] In another aspect, the invention provides pharmaceutical compositions comprising a compound of Formula (I) or (II), such as a compound of formula (I-1), (I-2), (I-3), (II-1), (II-2), and (II-3), administered with at least one pharmaceutically acceptable carrier or excipient, optionally administered with two or more pharmaceutically acceptable carriers or excipients.
The compounds may be used as pharmaceutically acceptable salts and hydrates.
The compounds may be used as pharmaceutically acceptable salts and hydrates.
[0053] In another aspect, the invention provides a method to treat a subject infected with influenza A, B or C, which comprises administering to a subject in need of such treatment an effective amount of a compound of Formula (I) or (II), such as a compound of formula (I-1), (I-2), (I-3), (II-1), (II-2), or (II-3), or any subgenus or species thereof as described herein, or a pharmaceutical composition comprising such compound. The subject is a human, although the compounds and methods of the invention are suitable for treatment of other species that contract Influenza A, Influenza B, or influenza C, as well as other influenza viruses.
[0054] The compounds as disclosed herein, their pharmaceutically acceptable salts, stereoisomers, solvates thereof, exhibit the ability and drug properties to inhibit or prevent replication of influenza virus, as indicated by test data provided below, and are therefore indicated for therapy to inhibit replication of an influenza virus, particularly Influenza A, Influenza B or Influenza C. Accordingly, compounds of the invention are useful in the treatment of an infection caused by an influenza virus, particularly Influenza A, Influenza B
or Influenza C, especially in human subjects having or at risk of contracting an influenza viral infection. For example, subjects having pre-existing conditions related to autoimmune or respiratory diseases that can be greatly exacerbated by an influenza infection may be treated with the methods or compounds of the invention before exhibiting symptoms of an influenza infection. In other aspects, the subject for treatment is one diagnosed as having symptoms consistent with an influenza infection. As a further aspect, the present invention provides the use of compounds as described herein as therapeutics. In particular, the compounds are suitable for use to treat a subject having or at particularly high risk for an influenza virus viral infection, especially Influenza A, Influenza B, or Influenza C.
or Influenza C, especially in human subjects having or at risk of contracting an influenza viral infection. For example, subjects having pre-existing conditions related to autoimmune or respiratory diseases that can be greatly exacerbated by an influenza infection may be treated with the methods or compounds of the invention before exhibiting symptoms of an influenza infection. In other aspects, the subject for treatment is one diagnosed as having symptoms consistent with an influenza infection. As a further aspect, the present invention provides the use of compounds as described herein as therapeutics. In particular, the compounds are suitable for use to treat a subject having or at particularly high risk for an influenza virus viral infection, especially Influenza A, Influenza B, or Influenza C.
[0055] In another aspect, the invention provides a method of treating a disease which is caused by an influenza virus, comprising administration of a therapeutically effective amount of a compound of formula (I) or (II) as described herein, such as a compound of formula (I-1), (I-2), (I-3), (II-1), (II-2), or (II-3), or a pharmaceutically acceptable salt, stereoisomer, solvate thereof, to a subject in need of such treatment. In some aspects, the compound or a pharmaceutically acceptable salt, stereoisomer, solvate thereof, is administered orally. In a further aspect, the disease is selected from Influenza A, Influenza B, and Influenza C. The method typically comprises administering an effective amount of a compound as described herein, or a pharmaceutical composition comprising an effective amount of such compound, to a subject in need of such treatment. The compound may be administered by any suitable method such as those described herein, and the administration may be repeated at intervals which may be selected by a physician. In some aspects, the compound or pharmaceutical composition is administered orally.
[0056] Thus, as a further aspect, the present invention provides the use of a compound of formula (I) or (II), such as a compound of formula (I-1), (I-2), (I-3), (II-1), (II-2), or (II-3), or a pharmaceutically acceptable salt, stereoisomer, solvate thereof, for the manufacture of a medicament. In a particular aspect, the medicament is for treatment of an influenza virus infection, especially Influenza A, Influenza B, or Influenza C.
[0057] The compound of the present invention may be administered either simultaneously with, or before or after, one or more therapeutic(s). The compound of the present invention may be administered separately, by the same or different route of administration, or together in the same pharmaceutical composition as the therapeutic(s). Suitable therapeutic(s) for use with the compounds of the invention include antivirals active on influenza viruses, such as neuraminidase inhibitors including oseltamivir, peramivir, zanamivir and laninamivir, laninamivir octanoate, and adamantanes such as amantadine and rimantadine.
Additionally, the compounds can be combined with an M2 protein inhibitor, a polymerase inhibitor, a PB2 inhibitor, favipiravir, fludase, beraprost, Neugene0, ribavirin, Flu Mist Quadrivalent , Fluarix0 Quadrivalent, Fluzone0 Quadrivalent, Flucelvax0 and FluBlok0 .
Additionally, the compounds can be combined with an M2 protein inhibitor, a polymerase inhibitor, a PB2 inhibitor, favipiravir, fludase, beraprost, Neugene0, ribavirin, Flu Mist Quadrivalent , Fluarix0 Quadrivalent, Fluzone0 Quadrivalent, Flucelvax0 and FluBlok0 .
[0058] In one aspect, the invention provides a product comprising a compound of formula (I) or (II), such as a compound of formula (I-1), (I-2), (I-3), (II-1), (II-2), or (II-3), or a pharmaceutically acceptable salt, stereoisomer, solvate thereof, and at least another therapeutic as a combined preparation for simultaneous, separate or sequential use in therapy.
[0059] The invention also provides a therapeutic for use in a method of treating a viral infection caused by an influenza virus, particularly Influenza A, Influenza B
or Influenza C, wherein the a therapeutic is administered with a compound of formula (I) or (II), such as a compound of formula (I-1), (I-2), (I-3), (II-1), (II-2), or (II-3), or a pharmaceutically acceptable salt, stereoisomer, solvate thereof
or Influenza C, wherein the a therapeutic is administered with a compound of formula (I) or (II), such as a compound of formula (I-1), (I-2), (I-3), (II-1), (II-2), or (II-3), or a pharmaceutically acceptable salt, stereoisomer, solvate thereof
[0060] The invention also provides the use of a compound of formula (I) or (II), such as a compound of formula (I-1), (I-2), (I-3), (II-1), (II-2), or (II-3), or a pharmaceutically acceptable salt, stereoisomer, solvate thereof, for treating a viral infection caused by an influenza virus, particularly influenza, such as Influenza A, Influenza B or Influenza C, wherein the patient has previously (e.g., within 24 hours) been treated with another therapeutic agent. The invention also provides the use of another therapeutic agent for treating a viral infection caused by an influenza virus, particularly Influenza A, Influenza B
or Influenza C, wherein the patient has previously (e.g., within 24 hours ) been treated with a compound of formula (I) or (II), or a pharmaceutically acceptable salt, stereoisomer, solvate thereof
or Influenza C, wherein the patient has previously (e.g., within 24 hours ) been treated with a compound of formula (I) or (II), or a pharmaceutically acceptable salt, stereoisomer, solvate thereof
[0061] In one aspect, the combination therapeutics is selected from antivirals purported to be useful for treating infections caused by influenza viruses, such as neuraminidase inhibitors including oseltamivir, peramivir, zanamivir and laninamivir, and adamantanes such as amantadine and rimantadine.
[0062] The pharmaceutical composition or combination of the present invention in human is dependent on the body weight, age and individual condition, the disorder or disease or the severity thereof being treated. The effective dose is determined by a physician or clinician to prevent, treat or inhibit the progress of the disorder or disease.
[0063] The above cited dosage properties are demonstrable in vitro and in vivo tests using advantageously mammals, such as mice, rats, dogs, monkeys or isolated organs, tissues and preparations thereof The invention further includes processes to make the compounds of Formulae (I) and (II), such as a compound of formula (I-1), (I-2), (I-3), (II-1), (II-2), or (II-3), as disclosed herein.
[0064] In the practice of the method of the present invention, a therapeutically effective amount of any one of the compounds of this invention or a combination of any of the compounds of this invention or a pharmaceutically acceptable salt or ester thereof, is administered via any of the usual and acceptable methods known in the art, either singly or in combination. The compounds or compositions can thus be administered orally (e.g., buccal cavity), sublingually, parenterally (e.g., intramuscularly, intravenously, or subcutaneously), rectally (e.g., by suppositories or washings), transdermally (e.g., skin electroporation) or by inhalation (e.g., by aerosol), and in the form of solid, liquid or gaseous dosages, including tablets and suspensions. The administration can be conducted in a single unit dosage form with continuous therapy or in a single dose therapy ad libitum. The therapeutic composition can also be in the form of an oil emulsion or dispersion in conjunction with a lipophilic salt such as pamoic acid, or in the form of a biodegradable sustained-release composition for subcutaneous or intramuscular administration.
[0065] The dose of a compound administered to an individual (such as a human) may vary with the particular compound or salt thereof, the method of administration, and the particular disease being treated. The effective amount of the compound may, in one aspect, be a daily dose of between about 0.01 and about 100 mg/kg of body weight; in some embodiments, from about 0.05 to 10.0 mg/kg of body weight, and in some embodiments, from about 0.10 to 1.4 mg/kg of body weight. For administration to a 70 kg person, in some embodiments, the dosage range would be about from 0.7 to 7000 mg per day; in some embodiments, about from 3.5 to 700.0 mg per day, and in some embodiments, about from 7 to 100.0 mg per day.
Effective amounts or doses of the compounds of the invention may be ascertained by routine methods, such as modeling, dose escalation, or clinical trials, taking into account factors, e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the agent, the severity and course of the disease to be treated, the subject's health status, condition, and weight. An exemplary dose is in the range of about from about 0.1 mg to 10 g daily. For example, an exemplary dosage range for oral administration is from about 5 mg to about 500 mg per day, and an exemplary intravenous administration dosage is from about 5 mg to about 500 mg per day, each depending upon the pharmacokinetics.
Effective amounts or doses of the compounds of the invention may be ascertained by routine methods, such as modeling, dose escalation, or clinical trials, taking into account factors, e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the agent, the severity and course of the disease to be treated, the subject's health status, condition, and weight. An exemplary dose is in the range of about from about 0.1 mg to 10 g daily. For example, an exemplary dosage range for oral administration is from about 5 mg to about 500 mg per day, and an exemplary intravenous administration dosage is from about 5 mg to about 500 mg per day, each depending upon the pharmacokinetics.
[0066] A compound or composition of the invention may be administered to an individual in accordance with an effective dosing regimen for a desired period of time or duration, such as at least about one month, at least about 2 months, at least about 3 months, at least about 6 months, or at least about 12 months or longer, which in some variations may be for the duration of the individual's life. In one variation, the compound is administered on a daily or intermittent schedule. The compound can be administered to an individual continuously (for example, at least once daily) over a period of time. The dosing frequency can also be less than once daily, e.g., about a once weekly dosing. The dosing frequency can be more than once daily, e.g., twice or three times daily. The dosing frequency can also be intermittent, including a 'drug holiday' (e.g., once daily dosing for 7 days followed by no doses for 7 days, repeated for any 14 day time period, such as about 2 months, about 4 months, about 6 months or more). Any of the dosing frequencies can employ any of the compounds described herein together with any of the dosages described herein.
Articles ofManufacture and Kits
Articles ofManufacture and Kits
[0067] The present disclosure further provides articles of manufacture comprising a compound of the disclosure or a salt thereof, composition, and unit dosages described herein in suitable packaging. In certain embodiments, the article of manufacture is for use in any of the methods described herein. Suitable packaging is known in the art and includes, for example, vials, vessels, ampules, bottles, jars, flexible packaging and the like. An article of manufacture may further be sterilized and/or sealed.
[0068] The present disclosure further provides kits for carrying out the methods of the disclosure, which comprises one or more compounds described herein or a composition comprising a compound described herein. The kits may employ any of the compounds disclosed herein. In one variation, the kit employs a compound described herein or a pharmaceutically acceptable salt thereof The kits may be used for any one or more of the uses described herein, and, accordingly, may contain instructions for the treatment of disease described herein.
[0069] Kits generally comprise suitable packaging. The kits may comprise one or more containers comprising any compound described herein. Each component (if there is more than one component) can be packaged in separate containers or some components can be combined in one container where cross-reactivity and shelf life permit.
[0070] The kits may be in unit dosage forms, bulk packages (e.g., multi-dose packages) or sub-unit doses. For example, kits may be provided that contain sufficient dosages of a compound as disclosed herein and/or a second pharmaceutically active compound useful for a disease detailed herein (e.g., hypertension) to provide effective treatment of an individual for an extended period, such as any of a week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 months, 7 months, 8 months, 9 months, or more. Kits may also include multiple unit doses of the compounds and instructions for use and be packaged in quantities sufficient for storage and use in pharmacies (e.g., hospital pharmacies and compounding pharmacies).
[0071] The kits may optionally include a set of instructions, generally written instructions, although electronic storage media (e.g., magnetic diskette or optical disk) containing instructions are also acceptable, relating to the use of component(s) of the methods of the present invention. The instructions included with the kit generally include information as to the components and their administration to an individual.
[0072] In some embodiments, the invention provides selenium and/or phosphine containing compounds.
[0073] Among the provided embodiments are:
[0074] Embodiment 1. A compound of Formula (A):
G, 0 0 (R4)P
*L N 1 N )0 rc3 N
X
(R1)n Se Formula A
or a pharmaceutically acceptable salt or solvate thereof, wherein:
Ri is independently selected from H and/or fluoro, n = 0-4;
R2 is independently selected from H and/or fluoro, n = 0-4;
R3 is selected from H, F, Cl, Br, Me, CN, and P(0)Me2;
R4 is independently selected from Me and/or fluoro, p = 0-3;
G is H or is a group selected from C(0)R, C(0)0R, C(0)NR'R, C(R')2-0-C(0)R, C(R')2-0C(0)0R, and C(R')2-0-C(0)NR, where each R is a group selected from C1-C6 alkyl, phenyl, pyridyl, C3-C6 cycloalkyl, and a 4-6 membered heterocyclic ring containing one or two heteroatoms selected from N, 0 and S as ring members ; and each R is optionally substituted with one or two groups selected from H, halo, CN, OH, amino, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-C3 haloalkoxy ; and each R' is independently selected from the group consisting of H and C1-C3 alkyl.
G, 0 0 (R4)P
*L N 1 N )0 rc3 N
X
(R1)n Se Formula A
or a pharmaceutically acceptable salt or solvate thereof, wherein:
Ri is independently selected from H and/or fluoro, n = 0-4;
R2 is independently selected from H and/or fluoro, n = 0-4;
R3 is selected from H, F, Cl, Br, Me, CN, and P(0)Me2;
R4 is independently selected from Me and/or fluoro, p = 0-3;
G is H or is a group selected from C(0)R, C(0)0R, C(0)NR'R, C(R')2-0-C(0)R, C(R')2-0C(0)0R, and C(R')2-0-C(0)NR, where each R is a group selected from C1-C6 alkyl, phenyl, pyridyl, C3-C6 cycloalkyl, and a 4-6 membered heterocyclic ring containing one or two heteroatoms selected from N, 0 and S as ring members ; and each R is optionally substituted with one or two groups selected from H, halo, CN, OH, amino, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-C3 haloalkoxy ; and each R' is independently selected from the group consisting of H and C1-C3 alkyl.
[0075] Embodiment 2. The compound of embodiment 1, wherein G = H, or a pharmaceutically acceptable salt or solvate thereof
[0076] Embodiment 3. The compound of embodiment 1, wherein G = C(0)R, C(0)0R, C(0)NR'R, C(R')2-0-C(0)R, C(R')2-0-C(0)0R, and C(R')2-0-C(0)NR, where each R
is a group selected from Cl- C6 alkyl, phenyl, pyridyl, C3-C6 cycloalkyl, and a 4-6 membered heterocyclic ring containing one or two heteroatoms selected from N, 0 and S
as ring members ; and each R is optionally substituted with one or two groups selected from H, halo, CN, OH, amino, Cl-C3 alkyl, phenyl, Cl-C4 alkoxy, Cl-C3 haloalkyl, and Cl-C3 haloalkoxy; and each R' is independently selected from the group consisting of H and Cl-C3 alkyl, or a pharmaceutically acceptable salt or solvate thereof
is a group selected from Cl- C6 alkyl, phenyl, pyridyl, C3-C6 cycloalkyl, and a 4-6 membered heterocyclic ring containing one or two heteroatoms selected from N, 0 and S
as ring members ; and each R is optionally substituted with one or two groups selected from H, halo, CN, OH, amino, Cl-C3 alkyl, phenyl, Cl-C4 alkoxy, Cl-C3 haloalkyl, and Cl-C3 haloalkoxy; and each R' is independently selected from the group consisting of H and Cl-C3 alkyl, or a pharmaceutically acceptable salt or solvate thereof
[0077] Embodiment 4. The compound of embodiment 1, wherein G = C(0)R, C(0)0R, C(R')2-0-C(0)R, and C(R')2-0-C(0)0R, where each R is a group selected from Cl-alkyl, phenyl, pyridyl, C3 - C6 cycloalkyl, and a 4-6 membered heterocyclic ring containing one or two heteroatoms selected from N, 0 and S as ring members ; and each R
is optionally substituted with one or two groups selected from H, halo, CN, OH, amino, Cl-C3 alkyl, phenyl, Cl- C4 alkoxy, Cl- C3 haloalkyl, and Cl- C3 haloalkoxy ; and each R' is independently selected from the group consisting of H and Cl- C3 alkyl, or a pharmaceutically acceptable salt or solvate thereof
is optionally substituted with one or two groups selected from H, halo, CN, OH, amino, Cl-C3 alkyl, phenyl, Cl- C4 alkoxy, Cl- C3 haloalkyl, and Cl- C3 haloalkoxy ; and each R' is independently selected from the group consisting of H and Cl- C3 alkyl, or a pharmaceutically acceptable salt or solvate thereof
[0078] Embodiment 5. The compound of embodiment 1, wherein G = C(0)R, C(0)0R, CH2-0-C(0)R, and CH2-0-C(0)0R, where each R is a group selected from Cl- C5 alkyl and each R is optionally substituted with one group selected from H, halo, CN, OH, amino, or a pharmaceutically acceptable salt or solvate thereof
[0079] Embodiment 6. The compound of embodiment 1, which is of the formula B:
G, 0 zt R )P
N 1( RNNO
X \ (ROM
(R1)n Se Formula B
, or a pharmaceutically acceptable salt or solvate thereof
G, 0 zt R )P
N 1( RNNO
X \ (ROM
(R1)n Se Formula B
, or a pharmaceutically acceptable salt or solvate thereof
[0080] Embodiment 7. The compound of embodiment 6, wherein R1 is independently selected from H and/or fluoro, n = 0-4; R2 is independently selected from H
and/or fluoro, n = 0-4; R3 is selected from H, F, Cl, Br, Me, CN, and P(0)Me2; G is H or a group selected from C(0)R, C(0)0R, C(0)NR'R, C(R')2-0-C(0)R, C(R')2-0-C(0)0R, and C(R')2-0-C(0)NR, where each R is a group selected from C1-C6 alkyl, phenyl, pyridyl, C3 cycloalkyl, and a 4-6 membered heterocyclic ring containing one or two heteroatoms selected from N, 0 and S as ring members ; and each R is optionally substituted with one or two groups selected from H, halo, CN, OH, amino, Cl- C3 alkyl, phenyl, Cl- C4 alkoxy, Cl- C3 haloalkyl, and Cl- C3 haloalkoxy ; and each R' is independently selected from the group consisting of H and Cl- C3 alkyl, or a pharmaceutically acceptable salt or solvate thereof
and/or fluoro, n = 0-4; R3 is selected from H, F, Cl, Br, Me, CN, and P(0)Me2; G is H or a group selected from C(0)R, C(0)0R, C(0)NR'R, C(R')2-0-C(0)R, C(R')2-0-C(0)0R, and C(R')2-0-C(0)NR, where each R is a group selected from C1-C6 alkyl, phenyl, pyridyl, C3 cycloalkyl, and a 4-6 membered heterocyclic ring containing one or two heteroatoms selected from N, 0 and S as ring members ; and each R is optionally substituted with one or two groups selected from H, halo, CN, OH, amino, Cl- C3 alkyl, phenyl, Cl- C4 alkoxy, Cl- C3 haloalkyl, and Cl- C3 haloalkoxy ; and each R' is independently selected from the group consisting of H and Cl- C3 alkyl, or a pharmaceutically acceptable salt or solvate thereof
[0081] Embodiment 8. The compound of embodiment 1, which is of the formula C:
G.,0 0 ON
X /
(R1)n Se Formula C
R1 is independently selected from H and/or fluoro, n = 0-4; G is H or a group selected from C(0)R, C(0)0R, C(0)NR'R, C(R')2-0-C(0)R, C(R')2-0-C(0)0R, and C(R')2-0-C(0)NR, where each R is a group selected from Cl- C6 alkyl, phenyl, pyridyl, C3 - C6 cycloalkyl, and a 4-6 membered heterocyclic ring containing one or two heteroatoms selected from N, 0 and S as ring members ; and each R is optionally substituted with one or two groups selected from H, halo, CN, OH, amino, Cl- C3 alkyl, phenyl, Cl- C4 alkoxy, Cl- C3 haloalkyl, and Cl- C3 haloalkoxy ; and each R' is independently selected from the group consisting of H
and Cl- C3 alkyl, or a pharmaceutically acceptable salt or solvate thereof
G.,0 0 ON
X /
(R1)n Se Formula C
R1 is independently selected from H and/or fluoro, n = 0-4; G is H or a group selected from C(0)R, C(0)0R, C(0)NR'R, C(R')2-0-C(0)R, C(R')2-0-C(0)0R, and C(R')2-0-C(0)NR, where each R is a group selected from Cl- C6 alkyl, phenyl, pyridyl, C3 - C6 cycloalkyl, and a 4-6 membered heterocyclic ring containing one or two heteroatoms selected from N, 0 and S as ring members ; and each R is optionally substituted with one or two groups selected from H, halo, CN, OH, amino, Cl- C3 alkyl, phenyl, Cl- C4 alkoxy, Cl- C3 haloalkyl, and Cl- C3 haloalkoxy ; and each R' is independently selected from the group consisting of H
and Cl- C3 alkyl, or a pharmaceutically acceptable salt or solvate thereof
[0082] Embodiment 9. The compound of embodiment 8, which is of the formula D:
G...0 0 OtyLN
Se Formula D
G is H or a group selected from C(0)R, C(0)0R, C(0)NR'R, C(R')2-0-C(0)R, C(R')2-0-C(0)0R, and C(R')2-0-C(0)NR, where each R is a group selected from Cl- C6 alkyl, phenyl, pyridyl, C3 - C6 cycloalkyl, and a 4-6 membered heterocyclic ring containing one or two heteroatoms selected from N, 0 and S as ring members ; and each R is optionally substituted with one or two groups selected from H, halo, CN, OH, amino, Cl-C3 alkyl, phenyl, Cl- C4 alkoxy, Cl- C3 haloalkyl, and Cl- C3 haloalkoxy; and each R' is independently selected from the group consisting of H and Cl- C3 alkyl, or a pharmaceutically acceptable salt or solvate thereof
G...0 0 OtyLN
Se Formula D
G is H or a group selected from C(0)R, C(0)0R, C(0)NR'R, C(R')2-0-C(0)R, C(R')2-0-C(0)0R, and C(R')2-0-C(0)NR, where each R is a group selected from Cl- C6 alkyl, phenyl, pyridyl, C3 - C6 cycloalkyl, and a 4-6 membered heterocyclic ring containing one or two heteroatoms selected from N, 0 and S as ring members ; and each R is optionally substituted with one or two groups selected from H, halo, CN, OH, amino, Cl-C3 alkyl, phenyl, Cl- C4 alkoxy, Cl- C3 haloalkyl, and Cl- C3 haloalkoxy; and each R' is independently selected from the group consisting of H and Cl- C3 alkyl, or a pharmaceutically acceptable salt or solvate thereof
[0083] Embodiment 10. The compound of embodiment 9, wherein G = C(0)R, C(0)0R, CH2-0-C(0)R, and CH2-0-C(0)0R, where each R is a group selected from Cl- C5 alkyl and each R is optionally substituted with one group selected from H, halo, CN, OH, amino, or a pharmaceutically acceptable salt or solvate thereof
[0084] Embodiment 11. A pharmaceutical composition comprising a compound of embodiment 1, or a pharmaceutically acceptable salt and solvate thereof, and one or more pharmaceutically acceptable carriers.
[0085] Embodiment 12. A method of treating influenza, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of embodiment 1, or a pharmaceutically acceptable salt and solvate thereof
[0086] The invention can be further understood by reference to the following examples, which are provided by way of illustration and are not meant to be limiting.
EXAMPLES
Synthetic Examples
EXAMPLES
Synthetic Examples
[0087] Reagents and solvates used below can be obtained from commercial sources. 11-1 NMR spectra were recorded on Varian III plus 300 MHz and TMS was used as an internal standard. Significant peaks are tabulated in the order: multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br s, broad singlet), coupling constant(s) in Hertz (Hz) and number of protons. Mass spectrometry results are reported as the ratio of mass over charge, followed by the relative abundance of each ion in parentheses Electrospray ionization (ES1) mass spectrometry analysis was conducted on a quadrupole Mass Spectrometer on Agilent LC/MSD 1200 Series (Column: Welchrom XB-C18 (50 x 4.6 mm, 5 um); T = 30 C;
flow rate = 1.5 ml/min. detected wavelength: 214 nm.
flow rate = 1.5 ml/min. detected wavelength: 214 nm.
[0088] The terms "solvent", "inert organic solvent", or "inert solvent" refer to a solvent inert under the conditions of the reaction being described in conjunction therewith including, for example, benzene, toluene, acetonitrile, tetrahydrofuran ("THF"), dimethylformamide ("DMF"), ethyl acetate (EA or Et0Ac), dichloromethane (DCM), diethyl ether, methanol, pyridine, formic acid (FA) and the like. Unless specified to the contrary, the solvates used in the reactions of the present invention are inert organic solvates, and the reactions are carried out under an inert gas, preferably nitrogen and argon.
Example 1 Synthesis of 12-(7,8-difitioro-6,11-dihydrodibenzo[b,eiselenepin-11-y1)-7-hydroxy-3,4, 12,12a-tetrahydro-1H-11,41oxazino[3,4-olpyrido[2,1-1][1,2,4_1triazine-6,8-dione (A-1) - -401 SeH
F F F OH
F 0 1. LDA F 401 CHO _ F 4 ___________________ w- ___________ 0 ¨ __ 2. DMF
COOH COOH
F Se . F Se F Se . F
F AlC13 F p-H3PO4 ______________________ ..-0 _________________________________________________ .
H, I I ,H
SSi 101 COOH 0 OBn 0 11 ON
F
Se F N,NO
NaBH4 F MsCl/TFA Se H
F ..-___________ . ___________________ ..-OH
OMs OBn 0 OH 0 0*N
o*.LN1 N,N)0 LiCI, DMF N,NO
___________________________ ..-F F
F
Se F Se Scheme 1. Synthesis of A-1
Example 1 Synthesis of 12-(7,8-difitioro-6,11-dihydrodibenzo[b,eiselenepin-11-y1)-7-hydroxy-3,4, 12,12a-tetrahydro-1H-11,41oxazino[3,4-olpyrido[2,1-1][1,2,4_1triazine-6,8-dione (A-1) - -401 SeH
F F F OH
F 0 1. LDA F 401 CHO _ F 4 ___________________ w- ___________ 0 ¨ __ 2. DMF
COOH COOH
F Se . F Se F Se . F
F AlC13 F p-H3PO4 ______________________ ..-0 _________________________________________________ .
H, I I ,H
SSi 101 COOH 0 OBn 0 11 ON
F
Se F N,NO
NaBH4 F MsCl/TFA Se H
F ..-___________ . ___________________ ..-OH
OMs OBn 0 OH 0 0*N
o*.LN1 N,N)0 LiCI, DMF N,NO
___________________________ ..-F F
F
Se F Se Scheme 1. Synthesis of A-1
[0089] Synthesis of 4,5-difluoro-3-hydroxyisobenzofuran-1(3H)-one (3) F F OH
F 40 1. LDA F
_______________________________________ _ 0 COOH 2. DMF
F 40 1. LDA F
_______________________________________ _ 0 COOH 2. DMF
[0090] To a solution of LDA (4.8 g, 0.045 mol) in THF (15 mL) was slowly added a solution of 3,4-difluorobenzoic acid (3 g, 0.019 mol) in THF (5 mL) at -40 C.
The reaction solution was stirred at -40 C for 1 hour, and DMF (3.45 g, 0.047 mol) was added slowly, 6 mol/L hydrochloric acid in water (20 mL) was added to the reaction mixture, and then the organic layer and the aqueous layer were separated. The obtained aqueous layer was extracted with ethyl acetate (30 mL). The organic layers were combined and concentrated to obtain crude compound 3 (3.55 g), which was used directly in the next step without further purification. MS Calcd: 186; MS Found: 185 ([M - H[-).
The reaction solution was stirred at -40 C for 1 hour, and DMF (3.45 g, 0.047 mol) was added slowly, 6 mol/L hydrochloric acid in water (20 mL) was added to the reaction mixture, and then the organic layer and the aqueous layer were separated. The obtained aqueous layer was extracted with ethyl acetate (30 mL). The organic layers were combined and concentrated to obtain crude compound 3 (3.55 g), which was used directly in the next step without further purification. MS Calcd: 186; MS Found: 185 ([M - H[-).
[0091] Synthesis of 4,5-difluoro-3-(phenylselanypisobenzofuran-1(3H)-one (5) SeH
F OH F Se 0 ___________________ 0
F OH F Se 0 ___________________ 0
[0092] To a solution of compound 3 (3.5 g, 19 mmol) in toluene (20 mL) was added compound 4 (2 g, 12.5 mmol) and D-camphorsulfonic acid (0.7 g, 3 mmol).The mixture was stirred at 60 C overnight and then cooled to 5 C. A sodium hydroxide aqueous solution (7 mL, 2 M) was added to the reaction solution. The temperature was raised to 25 C. The reaction solution was extracted with toluene (30 mL). The obtained organic layers were concentrated under reduced pressure, purified by flash column chromatography on silica gel (PE: EA =5:1) to afford compound 5 (3 g, yield 50%) as a white solid. 1H-NMR
(400 MHz, CDC13): 67.48-7.46 (d, J= 6.8 Hz, 2H), 7.42-7.34 (m, 1H), 7.30-7.16 (m, 4H), 6.97 (s, 1H).
MS Calcd: 326; MS Found: 325 ([M -
(400 MHz, CDC13): 67.48-7.46 (d, J= 6.8 Hz, 2H), 7.42-7.34 (m, 1H), 7.30-7.16 (m, 4H), 6.97 (s, 1H).
MS Calcd: 326; MS Found: 325 ([M -
[0093] Synthesis of 3,4-difluoro-2-((phenylselanyl)methyl)benzoic acid (7) F Se F Se AlC13 Ti 0 H, I I ,H COOH
Si Si
Si Si
[0094] A solution of aluminum chloride (0.8 g, 414 mmol) in toluene (20 mL) was stirred at 0 C. Then compound 6 (0.8 g, 6 mmol) in toluene (3 mL) was added dropwise to the reaction solution, and the temperature was raised to 25 C. The solution of compound 5 (1.5 g, 4.6 mmol) in toluene (5 mL) was slowly added to the reaction solution, and the mixture was stirred at 25 C for 2.5 hours. After addition of 15% aqueous sulfuric acid (5 mL), the resultedreaction mixture was stirred and the organic layer was separated and concentrated under reduced pressure to afford compound 7 (2 g) as a yellow solid, which was used directly in the next step without further purification. MS Calcd: 328; MS Found: 327 ([M-H]-).
[0095] Synthesis of 7,8-difluorodibenzo[b,elselenepin-11(6H)-one (8) F Se 4Ik Se p-H3PO4
[0096] Polyphosphoric acid (20 g) was stirred at 80 C and compound 7 (2 g, 4.6 mmol) was added thereto. The temperature was raised to 120 C and the reaction was kept for 3 hours. The reaction solution was cooled to 80 C, and water (10 mL) was added slowly. The reaction solution was then further cooled to 30 C, and water (20 mL) was added. The resulted mixture was extracted with ethyl acetate (30 mL). The organic layer was distilled off under reduced pressure and then purified by flash column chromatography on silica gel (PE:
EA =50:1) to afford compound 8 (560 mg, yield 36%) as a brown solid. 1H-NMR
(400 MHz, CDC13): 68.09 ¨ 8.07 (m, 1H), 7.40 - 7.18 (m, 3H), 7.00 ¨ 6.97 (m, 2H), 4.04 (s, 2H); MS
Calcd: 310; MS Found: 311 ([M+141+).
EA =50:1) to afford compound 8 (560 mg, yield 36%) as a brown solid. 1H-NMR
(400 MHz, CDC13): 68.09 ¨ 8.07 (m, 1H), 7.40 - 7.18 (m, 3H), 7.00 ¨ 6.97 (m, 2H), 4.04 (s, 2H); MS
Calcd: 310; MS Found: 311 ([M+141+).
[0097] Synthesis of 7,8-difluoro-6,11-dihydrodibenzo[b,elselenepin-11-ol (9) Se Se NaBH4
[0098] To a solution of compound 8 (560 mg, 1.8 mmol) in 2-propanol (5 mL) and (1.0 mL) was added NaOH (2 mg) and NaBH4 (24 mg, 0.65 mmol). The reaction mixture was stirred at 40 C for 2 hours and cooled to 25 C. Water (10 mL) was added to the reaction mixture, and water and HC1 were added to adjust the reaction mixture to pH = 6-7. The resulted mixture was extracted with EA (30 mL) and purified by flash column chromatography on silica gel (PE: EA = 10:0-10:1) to afford compound 9 (460 mg, yield 80%) as a yellow solid. 1H-NMR (300 MHz, CDC13): 67.68 - 7.66 (d, J = 7.5 Hz, 1H), 7.29 -7.22 (m, 3H), 7.15 - 7.05 (m, 2H), 6.21 ¨6.21 (d, J= 1.8 Hz, 1H), 4.48 (s, 2H), 2.49 ¨ 2.48 (d, J= 2.7 Hz, 1H); MS Calcd: 312; MS Found: 311 ([M - H]).
[0099] Synthesis of 7,8-difluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1 methanesulfonate (10) Se Se MsCl/TFA
OH OMs
OH OMs
[0100] To a solution of compound 9 (200 mg, 0.64 mmol) in DCM (15 mL) was added TEA (194 mg, 1.9 mmol) at 0 C, then MsC1 (111 mg, 0.96 mmol) was added under atmosphere. The reaction was stirred at 0 C for 2 hours. The reaction was diluted with DCM
(20 mL), washed with HC1 (1N, 10 ml*3), brine. The organic phase was dried over Na2SO4, filtered and removed solvent under reduce pressure to afford crude compound 10 (175 mg), as a yellow oil, which was used directly in next step without further purification.
(20 mL), washed with HC1 (1N, 10 ml*3), brine. The organic phase was dried over Na2SO4, filtered and removed solvent under reduce pressure to afford crude compound 10 (175 mg), as a yellow oil, which was used directly in next step without further purification.
[0101] Synthesis of 7-(benzyloxy)-12-(7,8-difluoro-6,11-dihydrodibenzo[b,e1selenepin-11-y1)-3,4,12,12a-tetrahydro-1H41,41oxazino[3,4-c1pyrido[2,1-f][1,2,41triazine-6,8-dione (12) OBn 0 11 OBn 0 ON *LN
Se 0Ms Se
Se 0Ms Se
[0102] To a suspension of compound 10 (130 mg, 0.397 mmol) in MeCN (10 mL) was added K2CO3(82 mg, 0.596 mmol). After stirred at r.t. for 1 hour, the crude compound 11 (232 mg, 0.596 mmol, made in a similar manner as described in JP5971830B1) was added, then the reaction mixture was stirred at r.t. overnight. The reaction was diluted with EA (30 mL), washed with water and brine, and concentrated before being purified by prep-HPLC to afford compound 12 (85 mg, yield 34.4%) as a yellow solid. MS Calcd: 621; MS
Found: 622 ([M + Fir).
Found: 622 ([M + Fir).
[0103] Synthesis of 12-(7,8-difluoro-6,11-dihydrodibenzo[b,e1selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H41,41oxazino[3,4-c1pyrido[2,1-f][1,2,41triazine-6,8-dione (A-1) OBn 0 OH 0 OtyN o*LN
N,NO LiCI, DMF NNO
Se Se
N,NO LiCI, DMF NNO
Se Se
[0104] To a solution of compound 12 (50 mg, 0.08 mmol) in NMP (1.5 mL) was added LiC1 (34 mg, 0.8 mmol) at 80 C overnight. The reaction was cooled to room temperature and purified by Prep-HPLC to afford two fractions of A-1 (P1, 7 mg and P2, 7 mg) as a light yellow solid. A-1-P1 and A-1-P2 each are both a mixture of two diastereomers.
[0105] A-1-P1: 11-1-NMR (400 MHz, CDC13): 67.31-7.22 (m, 2H), 7.14-6.98 (m, 3H), 6.93-6.89 (m, 1H), 6.72-6.70 (d, J= 7.6 Hz, 1H), 6.08-6.06 (d, J= 7.6 Hz, 1H), 5.34 (s, 1H), 5.18-5.14 (m, 1H), 4.71-4.66 (m, 2H), 4.10-4.03 (m, 2H), 3.86-3.82 (m, 1H), 3.66-3.60 (m, 1H), 3.52-3.46 (m, 1H), 3.07-3.00 (m, 1H). LCMS [mobile phase: from 95% water (0.1%
TFA) and 5% acetonitrile to 5% water (0.1% TFA) and 95% acetonitrile in 6 min, finally under these conditions for 0.5 min.] purity is >95%, Rt = 3.604 min; MS Calcd.: 531;
MS Found:
532 ([M+1]+).
TFA) and 5% acetonitrile to 5% water (0.1% TFA) and 95% acetonitrile in 6 min, finally under these conditions for 0.5 min.] purity is >95%, Rt = 3.604 min; MS Calcd.: 531;
MS Found:
532 ([M+1]+).
[0106] A-1-P2: 11-1-NMR (400 MHz, CDC13): 67.36-7.18 (m, 4H), 6.93-6.89 (m, 2H), 6.64-6.61 (m, 1H), 6.20-6.17 (d, J= 8 Hz, 1H), 5.45-5.41(m, 1H), 5.17 (s, 1H), 4.57-4.51 (m, 2H), 4.13-4.08 (m, 2H), 3.80-3.76 (m, 1H), 3.61-3.56 (m, 1H), 3.47-3.42 (m, 1H), 2.77-2.72 (m, 1H). LCMS [mobile phase: from 70% water (0.1% TFA) and 30% acetonitrile to 30%
water (0.1% TFA) and 70% acetonitrile in 6 min, finally under these conditions for 0.5 min.] purity is >96%, Rt = 3.276 min; MS Calcd.: 531; MS Found: 532 ([M+1]+).
water (0.1% TFA) and 70% acetonitrile in 6 min, finally under these conditions for 0.5 min.] purity is >96%, Rt = 3.276 min; MS Calcd.: 531; MS Found: 532 ([M+1]+).
[0107] A mixture of stereoisomers (including, for example, a pair of enantiomers or a mixture of diastereomers) may be separated by any suitable method, including, but not limited to, chiral HPLC. When a mixture of stereoisomers is separated by HPLC, it is to be appreciated that the resultant individual stereoisomers or mixtures will be assigned sequential labels (e.g., P1, P2, etc.), the order of which implies the order in which the isomers eluted from the HPLC column. In this Example, when the mixture of A-1 is separated by HPLC, it is to be appreciated that the first-eluting mixture of disasteromers is labeled "P1," and the second-eluting mixture of disasteromers is labeled "P2." The absolute stereochemistry for "P1" and "P2" may be obtained by known methods.
Synthesis of compounds A-2 to A-9
Synthesis of compounds A-2 to A-9
[0108] Compounds A-2 to A-9 are synthesized in a similar manner as A-1 from the corresponding starting materials substituted 2-formylbenzoic acids.
CO2H *LN tY. N
CHO
R= F, H Se Se OHO OHO
*.LN 01,)LNI
,N
Se Se Se OHO OHO OHO
*.LN 0T)LNI 0T)LNI
N N
N N N N
Se Se Se
CO2H *LN tY. N
CHO
R= F, H Se Se OHO OHO
*.LN 01,)LNI
,N
Se Se Se OHO OHO OHO
*.LN 0T)LNI 0T)LNI
N N
N N N N
Se Se Se
[0109] In some embodiments, provided herein is a compound selected from the group consisting of:
8-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4loxazino[3,4-clpyrido[2,14][1,2,4]triazine-6,8-dione (A-2), 7-fluoro-6,11 -dihy drodibenzo[b,e] selenepin-1 1-y1)-7-hy droxy-3,4,12,12a-tetrahy dro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f] [1,2,4]triazine-6,8-dione (A-3), 8,9-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f] [1,2,4]triazine-6,8-dione (A-4), 10-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,41oxazino[3,4-clpyrido[2,1-f][1,2,41triazine-6,8-dione (A-5), 6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,41oxazino[3,4-clpyrido[2,1-f][1,2,41triazine-6,8-dione (A-6), 7,8,10-trifluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-3,4,12,12a-tetrahydro-1H-[1,41oxazino[3,4-clpyrido[2,1-f][1,2,41triazine-6,8-dione (A-7), 7,10-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H41,41oxazino[3,4-clpyrido[2,1-f][1,2,41triazine-6,8-dione (A-8), and 9-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,41oxazino[3,4-clpyrido[2,1-f][1,2,41triazine-6,8-dione (A-9).
Example 2 Synthesis of (R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,eiselenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-11,41oxazino[3,4-olpyrido[2,1-1][1,2,41triazine-6,8-dione (B-1) o)Y( N
N,N),N80 Se
8-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4loxazino[3,4-clpyrido[2,14][1,2,4]triazine-6,8-dione (A-2), 7-fluoro-6,11 -dihy drodibenzo[b,e] selenepin-1 1-y1)-7-hy droxy-3,4,12,12a-tetrahy dro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f] [1,2,4]triazine-6,8-dione (A-3), 8,9-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f] [1,2,4]triazine-6,8-dione (A-4), 10-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,41oxazino[3,4-clpyrido[2,1-f][1,2,41triazine-6,8-dione (A-5), 6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,41oxazino[3,4-clpyrido[2,1-f][1,2,41triazine-6,8-dione (A-6), 7,8,10-trifluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-3,4,12,12a-tetrahydro-1H-[1,41oxazino[3,4-clpyrido[2,1-f][1,2,41triazine-6,8-dione (A-7), 7,10-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H41,41oxazino[3,4-clpyrido[2,1-f][1,2,41triazine-6,8-dione (A-8), and 9-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,41oxazino[3,4-clpyrido[2,1-f][1,2,41triazine-6,8-dione (A-9).
Example 2 Synthesis of (R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,eiselenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-11,41oxazino[3,4-olpyrido[2,1-1][1,2,41triazine-6,8-dione (B-1) o)Y( N
N,N),N80 Se
[0110] Synthesis of (R)-7-(benzyloxy)-3,4,12,12a-tetrahydro-1H41,41oxazino[3,4-clpyrido[2,1-f][1,2,41triazine-6,8-dione (11-R) OBn 0 OBn 0 0*=LN Chiral separation o*LN
H H
H H
[0111] Compound 11 (7.0 g, 21.4 mmol) was separated with chiral HPLC: 60-40%
CO2, solvent (Me0H), column (IA). Collect peak 1 to obtained 11-R (3.2 g, yield 45.7%).
CO2, solvent (Me0H), column (IA). Collect peak 1 to obtained 11-R (3.2 g, yield 45.7%).
[0112] Synthesis of (R)-7-(hexyloxy)-3,4,12,12a-tetrahydro-1H41,41oxazino[3,4-clpyrido[2,1-f][1,2,41triazine-6,8-dione (13) OBn 0 OH
0*=LN ________________________________________ 0 0 iPrMgCI *LN
0*=LN ________________________________________ 0 0 iPrMgCI *LN
[0113] To a solution of hexan-l-ol (5.5 g, 55 mmol) in THF (12 mL) was added i-PrMgC1 (3.7 mL, 3.7 mmol), and the mixture was stirred at room temperature for 0.5 h.
The solution was added to a suspension of compound 11-R(3.0 g, 9.17 mmol) in hexan-l-ol (5.5 g, 55 mmol), then stirred at room temperature for 24 h. The reaction was quenched by HC1 (1N) to pH7, extracted with Et0Ac (20 mL*3) and purified by flash column chromatography on silica gel (DCM:Me0H=10:1) to afford compound 13 (2.3 g, yield 78.2%) as a white solid, which was used in next step without further purification. MS Calcd: 321; MS
Found: 322 ([M+H]+).
The solution was added to a suspension of compound 11-R(3.0 g, 9.17 mmol) in hexan-l-ol (5.5 g, 55 mmol), then stirred at room temperature for 24 h. The reaction was quenched by HC1 (1N) to pH7, extracted with Et0Ac (20 mL*3) and purified by flash column chromatography on silica gel (DCM:Me0H=10:1) to afford compound 13 (2.3 g, yield 78.2%) as a white solid, which was used in next step without further purification. MS Calcd: 321; MS
Found: 322 ([M+H]+).
[0114] The above description of synthesis of compound 13 from 11-R can be catalyzed by other reagents such as Li salts or K salts other than iPrMgCl. For example, LDA (lithium diisopropylamide), alkyoxy Li salts or K salts, LHMDS (lithium bis(trimethylsilyl)amide), or KHMDS (potassium bis(trimethylsilyl)amide) were applied to the conversion of compound 11-R to compound 13.
Li salts & K salts _____________________________ OLi ) OK
_____________________________ OLi ) OK
LHMDS KHMDS
Li salts & K salts _____________________________ OLi ) OK
_____________________________ OLi ) OK
LHMDS KHMDS
[0115] Synthesis of (R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e1selenepin-11-y1)-7-(hexyloxy)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,41triazine-6,8-dione (14) OH
0 FJ tY.LN
o SeNNLo 9 )YLN N, T3P, MeS03H
H H
Se
0 FJ tY.LN
o SeNNLo 9 )YLN N, T3P, MeS03H
H H
Se
[0116] To a suspension of compound 13(1.7 g, 5.29 mmol) in EA (12 mL) was added hexane (3.5 mL), compound 9 (1.65 g, 5.3 mmol), T3P (6.75 g, 10.6 mmol), MeS03H (1.7 g, 17.7 mmol). The reaction was stirred at 60 C overnight, and LCMS showed that most of compound 13 was converted to compound 14. The reaction mixture wascooled down to r.t, diluted with EA (30 mL), added 20% NaOH to pH>8, extracted with EA, dried over Na2SO4, concentrated and purified by Prep-HPLC (0.1% TFA) to obtain compound 14 (1.06 g, yield 32.6%) as an off-white solid. MS Calcd: 615; MS Found: 616 ([M+H]+).
[0117] Synthesis of (R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (B-1) 0 0 yN
o*LN
LiCI, DMF O L
Se Se
o*LN
LiCI, DMF O L
Se Se
[0118] To a suspension of compound 14(1.06 g, 1.72 mmol) in NMP (5 mL) was added LiC1 (724 mg, 17.2 mmol), then the reaction mixture was stirred at 90 C for 24h. The reaction was purified by Prep-HPLC (0.1%TFA) to afford compound B-1 (367 mg, 86.3%) as a white solid. 11-1-NMR (400 MHz, DMSO-d6): 67.41-7.30 (m, 2H), 7.26-7.19 (m, 2H), 7.13-7.06 (m, 2H), 6.92-6.88 (m, 1H), 5.81 (s, 1H), 5.61-5.59 (d, J= 7.6Hz, 1H), 5.31-5.27 (dd, J
= 2Hz and 12.4Hz, 1H), 4.61-4.58 (m, 1H), 4.45-4.42 (m, 1H), 4.13-4.10 (d, J =
12.8Hz, 1H), 4.04-4.01 (m, 1H), 3.70-3.64 (m, 2H), 3.46-3.40 (m, 1H), 3.09-3.02 (m, 1H).
LCMS [mobile phase: from 80% water (0.1% TFA) and 20% acetonitrile to 30% water (0.1% TFA) and 70%
acetonitrile in 6 min, finally under these conditions for 0.5 min.] purity is >98%, Rt = 3.793 min; MS Calcd.: 531; MS Found: 532 ([M+11+).
Synthesis of compounds B-2 to B-9
= 2Hz and 12.4Hz, 1H), 4.61-4.58 (m, 1H), 4.45-4.42 (m, 1H), 4.13-4.10 (d, J =
12.8Hz, 1H), 4.04-4.01 (m, 1H), 3.70-3.64 (m, 2H), 3.46-3.40 (m, 1H), 3.09-3.02 (m, 1H).
LCMS [mobile phase: from 80% water (0.1% TFA) and 20% acetonitrile to 30% water (0.1% TFA) and 70%
acetonitrile in 6 min, finally under these conditions for 0.5 min.] purity is >98%, Rt = 3.793 min; MS Calcd.: 531; MS Found: 532 ([M+11+).
Synthesis of compounds B-2 to B-9
[0119] Compounds B-2 to B-9 are obtained in a similar manner as compound B-1.
OHO OHO
**N OLLN
Se Se OHO OHO
*N *N *.L1\1 Se Se Se OHO OHO OHO
tYLN *.LN *LN
Se Se Se
OHO OHO
**N OLLN
Se Se OHO OHO
*N *N *.L1\1 Se Se Se OHO OHO OHO
tYLN *.LN *LN
Se Se Se
[0120] In some embodiments, provided herein is a compound selected from the group consisting of:
(R)-12-((S)-8-fluoro-6,11-dihy drodibenzo[b,e1 selenepin-11-y1)-7-hy droxy-3,4,12,12a-tetrahydro-1H41,41oxazino[3,4-c] pyrido [2,1-f] [1,2,4]triazine-6,8-dione (B-2), (R)-12-((S)-7-fluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4loxazino[3,4-clpyrido[2,1-f][1,2,4]triazine-6,8-dione (B-3), (R)-12-((S)-8,9-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4loxazino[3,4-clpyrido[2,1-f][1,2,4]triazine-6,8-dione (B-4), (R)-12-((S)-10-fluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H41,4loxazino[3,4-clpyrido[2,1-f][1,2,4]triazine-6,8-dione (B-5), (R)-12-((S)-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4loxazino[3,4-clpyrido[2,1-f][1,2,4]triazine-6,8-dione (B-6), (R)-12-((S)-7,8,10-trifluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-3,4,12,12a-tetrahydro-1H41,4loxazino[3,4-clpyrido[2,1-f][1,2,4]triazine-6,8-dione (B-7), (R)-12-((S)-7,10-difluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4loxazino[3,4-clpyrido[2,1-f][1,2,4]triazine-6,8-dione (B-8), and (R)-12-((S)-9-fluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4loxazino[3,4-clpyrido[2,1-f][1,2,4]triazine-6,8-dione (B-9).
Example 3 Synthesis of methyl 2-((((R)-12-((S)- 7, 8-difitioro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,14][1,2,4]triazin- 7-yl)oxy)methoxy)acetate (C-1) OHO
Oty=LN 0 L
N, C10).LO
- y=L
KI, K2CO3 O
Se Se
(R)-12-((S)-8-fluoro-6,11-dihy drodibenzo[b,e1 selenepin-11-y1)-7-hy droxy-3,4,12,12a-tetrahydro-1H41,41oxazino[3,4-c] pyrido [2,1-f] [1,2,4]triazine-6,8-dione (B-2), (R)-12-((S)-7-fluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4loxazino[3,4-clpyrido[2,1-f][1,2,4]triazine-6,8-dione (B-3), (R)-12-((S)-8,9-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4loxazino[3,4-clpyrido[2,1-f][1,2,4]triazine-6,8-dione (B-4), (R)-12-((S)-10-fluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H41,4loxazino[3,4-clpyrido[2,1-f][1,2,4]triazine-6,8-dione (B-5), (R)-12-((S)-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4loxazino[3,4-clpyrido[2,1-f][1,2,4]triazine-6,8-dione (B-6), (R)-12-((S)-7,8,10-trifluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-3,4,12,12a-tetrahydro-1H41,4loxazino[3,4-clpyrido[2,1-f][1,2,4]triazine-6,8-dione (B-7), (R)-12-((S)-7,10-difluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4loxazino[3,4-clpyrido[2,1-f][1,2,4]triazine-6,8-dione (B-8), and (R)-12-((S)-9-fluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4loxazino[3,4-clpyrido[2,1-f][1,2,4]triazine-6,8-dione (B-9).
Example 3 Synthesis of methyl 2-((((R)-12-((S)- 7, 8-difitioro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,14][1,2,4]triazin- 7-yl)oxy)methoxy)acetate (C-1) OHO
Oty=LN 0 L
N, C10).LO
- y=L
KI, K2CO3 O
Se Se
[0121] To a suspension of compound B-1 (400 mg, 0.75 mmol) in DMA (10 mL) was added chloromethyl methyl carbonate (187 mg, 1.5 mmol), K2CO3 (210 mg, 1.5 mmol), KI
(125 mg, 0.75 mmol), then the reaction mixture was stirred at 50 C overnight. The reaction was diluted with EA (20 mL), washed with water, followed by brine, purified by Prep-HPLC
(0.1%TFA) to afford compound C-1 (237 mg, 50.8%) as a white solid.1H-NMR (400 MHz, DMSO-d6):
67.36-7.34 (d, J= 7.6Hz, 1H), 7.27 (s, 1H), 7.22-7.20 (d, J= 8Hz, 1H), 7.13-6.84 (m, 5H), 6.18-6.16 (d, J= 7.6Hz, 1H), 5.88 (s, 2H), 5.40 (s, 1H), 5.18-5.15 (dd, J=
2.8Hz and 12.8Hz, 1H), 4.65-4.60 (m, 2H), 4.08-3.99 (m, 2H), 3.86 (s, 3H), 3.81-3.77 (m, 1H), 3.58-3.42 (m, 2H), 3.01-2.93 (m, 1H). LCMS [mobile phase: from 70% water (0.1% TFA) and 30%
acetonitrile to 30% water (0.1% TFA) and 70% acetonitrile in 6 min, finally under these conditions for 0.5 min.] purity is >97%, Rt = 3.424 min; MS Calcd.: 619; MS Found: 620 ([M+1]+).
Synthesis of compounds C-2 to C-9
(125 mg, 0.75 mmol), then the reaction mixture was stirred at 50 C overnight. The reaction was diluted with EA (20 mL), washed with water, followed by brine, purified by Prep-HPLC
(0.1%TFA) to afford compound C-1 (237 mg, 50.8%) as a white solid.1H-NMR (400 MHz, DMSO-d6):
67.36-7.34 (d, J= 7.6Hz, 1H), 7.27 (s, 1H), 7.22-7.20 (d, J= 8Hz, 1H), 7.13-6.84 (m, 5H), 6.18-6.16 (d, J= 7.6Hz, 1H), 5.88 (s, 2H), 5.40 (s, 1H), 5.18-5.15 (dd, J=
2.8Hz and 12.8Hz, 1H), 4.65-4.60 (m, 2H), 4.08-3.99 (m, 2H), 3.86 (s, 3H), 3.81-3.77 (m, 1H), 3.58-3.42 (m, 2H), 3.01-2.93 (m, 1H). LCMS [mobile phase: from 70% water (0.1% TFA) and 30%
acetonitrile to 30% water (0.1% TFA) and 70% acetonitrile in 6 min, finally under these conditions for 0.5 min.] purity is >97%, Rt = 3.424 min; MS Calcd.: 619; MS Found: 620 ([M+1]+).
Synthesis of compounds C-2 to C-9
[0122] Compounds C-2 to C-9 are obtained in a similar manner as compound C-1.
0).LOO 0 OA00 0 o*( N otY. N
NN-LON N
S
Se e OyLJL
N o)Y.L N
0*.L N
N,N)N4.0 N N N N
Se Se Se 0).LOO 0 0).LOO 0 0).LOO 0 o*L N o**L N o*L N
N ,N
Se Se Se
0).LOO 0 OA00 0 o*( N otY. N
NN-LON N
S
Se e OyLJL
N o)Y.L N
0*.L N
N,N)N4.0 N N N N
Se Se Se 0).LOO 0 0).LOO 0 0).LOO 0 o*L N o**L N o*L N
N ,N
Se Se Se
[0123] In some embodiments, provided herein is a compound selected from the group consisting of:
(((R)-12-((S)-8-fluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,41oxazino[3,4-c1pyrido[2,1-f][1,2,41triazin-7-y1)oxy)methyl methyl carbonate (C-2), (((R)-12-((S)-7-fluoro-6,11-dihydrodibenzo[b,e1selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c1pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (C-3), (((R)-12-((S)-8,9-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,4loxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-y1)oxy)methyl methyl carbonate (C-4), (((R)-12-((S)-10-fluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (C-5), (((R)-12-((S)-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,4loxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-y1)oxy)methyl methyl carbonate (C-6), (((R)-6,8-dioxo-12-((S)-7,8,10-trifluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (C-7), (((R)-12-((S)-7,10-difluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (C-8), and (((R)-12-((S)-9-fluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (C-9).
Example 4 Synthesis of compounds D-1 to D-9
(((R)-12-((S)-8-fluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,41oxazino[3,4-c1pyrido[2,1-f][1,2,41triazin-7-y1)oxy)methyl methyl carbonate (C-2), (((R)-12-((S)-7-fluoro-6,11-dihydrodibenzo[b,e1selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c1pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (C-3), (((R)-12-((S)-8,9-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,4loxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-y1)oxy)methyl methyl carbonate (C-4), (((R)-12-((S)-10-fluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (C-5), (((R)-12-((S)-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,4loxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-y1)oxy)methyl methyl carbonate (C-6), (((R)-6,8-dioxo-12-((S)-7,8,10-trifluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (C-7), (((R)-12-((S)-7,10-difluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (C-8), and (((R)-12-((S)-9-fluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (C-9).
Example 4 Synthesis of compounds D-1 to D-9
[0124] Compounds D-1 to D-9 are obtained according to the following condition:
To an aqueous (1.0 mL) suspension of compound B-1 (0.10 mmol) and potassium carbonate (138 mg, 0.22 mmol) are added tetrabutylammonium hydrogen sulfate (34 mg, 0.10 mmol) and dichloromethane (0.5 mL), and the mixture is stirred at room temperature for 10 minutes. To the reaction solution is added a dichloromethane (0.5 mL) solution of corresponding iodide (0.22 mmol), and the mixture is further stirred for 2 hours. Thereafter, to the reaction solution is added water, the dichloromethane layer is separated, and the aqueous layer is extracted with dichloromethane once. The combined extracts are washed with brine and then dried over sodium sulfate. The solvent is concentrated and the residue is purified by silica gel column chromatography.
).L00 0 (21)-LOO 0 0000 *.LN *I\I **LN
N,N).%.0 1.1 F F F
Se F Se F Se F
)0)L00 0 AO 0 0)(00 0 )YLN
N,N0 N,N)=.%.0 N,N).Ni.0 F F F
Se Se Se F F F
(si)L00 0 1)A010 0 1)L(DO 0 NH2 0)y-N NH2 0*-LN NH2 0*Lr\i N ii 0,,, N,NL,%.0 _ F F F
Se Se Se F F F
To an aqueous (1.0 mL) suspension of compound B-1 (0.10 mmol) and potassium carbonate (138 mg, 0.22 mmol) are added tetrabutylammonium hydrogen sulfate (34 mg, 0.10 mmol) and dichloromethane (0.5 mL), and the mixture is stirred at room temperature for 10 minutes. To the reaction solution is added a dichloromethane (0.5 mL) solution of corresponding iodide (0.22 mmol), and the mixture is further stirred for 2 hours. Thereafter, to the reaction solution is added water, the dichloromethane layer is separated, and the aqueous layer is extracted with dichloromethane once. The combined extracts are washed with brine and then dried over sodium sulfate. The solvent is concentrated and the residue is purified by silica gel column chromatography.
).L00 0 (21)-LOO 0 0000 *.LN *I\I **LN
N,N).%.0 1.1 F F F
Se F Se F Se F
)0)L00 0 AO 0 0)(00 0 )YLN
N,N0 N,N)=.%.0 N,N).Ni.0 F F F
Se Se Se F F F
(si)L00 0 1)A010 0 1)L(DO 0 NH2 0)y-N NH2 0*-LN NH2 0*Lr\i N ii 0,,, N,NL,%.0 _ F F F
Se Se Se F F F
[0125] In some embodiments, provided herein is a compound selected from the group consisting of:
(1(R)-12-1(S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-clpyrido[2,1-f][1,2,41triazin-7-yl)oxy)methyl ethyl carbonate (D-1), 1-(((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,41oxazino[3,4-c1pyrido[2,1-f][1,2,41triazin-7-yl)oxy)ethyl methyl carbonate (D-2), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-c]pyrido[2,1-f][1,2,41triazin-7-yl)oxy)methyl acetate (D-3), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-c]pyrido[2,1-f][1,2,41triazin-7-yl)oxy)methyl isopropyl carbonate (D-4), (R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,41oxazino[3,4-c]pyrido[2,1-f][1,2,41triazin-7-y1 acetate (D-5), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-c]pyrido[2,1-f][1,2,41triazin-7-yl)oxy)methyl (2-methoxyethyl) carbonate (D-6), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-c]pyrido[2,1-f][1,2,41triazin-7-y0oxy)methyl L-valinate (D-7), 1-(((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e1selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-c1pyrido[2,1-f][1,2,41triazin-7-y0oxy)ethyl L-valinate (D-8), and (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-c]pyrido[2,1-f][1,2,41triazin-7-yl)oxy)methyl L-leucinate (D-9).
Example 5 7-(benzyloxy)-9-bromo-12-(7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-y1)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (15) OH
OBn 0 OBn 0 0 OBn 0 o*.LN
N,NO
NBS Dr T3P/MeS03H DMF
(1(R)-12-1(S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-clpyrido[2,1-f][1,2,41triazin-7-yl)oxy)methyl ethyl carbonate (D-1), 1-(((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,41oxazino[3,4-c1pyrido[2,1-f][1,2,41triazin-7-yl)oxy)ethyl methyl carbonate (D-2), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-c]pyrido[2,1-f][1,2,41triazin-7-yl)oxy)methyl acetate (D-3), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-c]pyrido[2,1-f][1,2,41triazin-7-yl)oxy)methyl isopropyl carbonate (D-4), (R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,41oxazino[3,4-c]pyrido[2,1-f][1,2,41triazin-7-y1 acetate (D-5), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-c]pyrido[2,1-f][1,2,41triazin-7-yl)oxy)methyl (2-methoxyethyl) carbonate (D-6), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-c]pyrido[2,1-f][1,2,41triazin-7-y0oxy)methyl L-valinate (D-7), 1-(((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e1selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-c1pyrido[2,1-f][1,2,41triazin-7-y0oxy)ethyl L-valinate (D-8), and (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-c]pyrido[2,1-f][1,2,41triazin-7-yl)oxy)methyl L-leucinate (D-9).
Example 5 7-(benzyloxy)-9-bromo-12-(7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-y1)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (15) OH
OBn 0 OBn 0 0 OBn 0 o*.LN
N,NO
NBS Dr T3P/MeS03H DMF
[0126] Step 1. To a suspension of compound 11 (150 mg, 0.458 mmol) in EA (3.2 mL) was added hexane (1.25 mL), stirred at r.t for 10min, added T3P (1.5 g, 2.36 mmol) and the mixture was stirred at r.t. for 30 min, added 7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-ol (175 mg, 0.51 mmol) and the reaction mixture was stirred at 35 C overnight, added MeS03H (80 mg, 0.83 mmol), 7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-ol (178 mg, 0.67 mmol) in EA (0.5 mL). The mixture was stirred at 55 C overnight and LCMS
showed that most of compound 11 disappeared. The mixture was cooled down to r.t, diluted with EA
(30 mL), washed with water, brine, dried over Na2SO4, filtered and the filtrate was evaporated. The residue was slurried in MTBE (10 mL) and PE (20 mL), filtered and dried in vacuum to afford compound 7-(benzyloxy)-12-(7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-3,4,12,12a-tetrahydro-1H41,4]oxazino[3,4-clpyrido[2,1-f][1,2,4]triazine-6,8-dione (205 mg, yield 78.1%) as a yellow solid, which was used directly in next step without further purification. MS Calcd: 573; MS Found: 574 (M +
H+).
showed that most of compound 11 disappeared. The mixture was cooled down to r.t, diluted with EA
(30 mL), washed with water, brine, dried over Na2SO4, filtered and the filtrate was evaporated. The residue was slurried in MTBE (10 mL) and PE (20 mL), filtered and dried in vacuum to afford compound 7-(benzyloxy)-12-(7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-3,4,12,12a-tetrahydro-1H41,4]oxazino[3,4-clpyrido[2,1-f][1,2,4]triazine-6,8-dione (205 mg, yield 78.1%) as a yellow solid, which was used directly in next step without further purification. MS Calcd: 573; MS Found: 574 (M +
H+).
[0127] Step 2. To a mixture of 7-(benzyloxy)-12-(7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-3,4,12,12a-tetrahydro-1H41,4loxazino[3,4-clpyrido[2,1-f][1,2,4]triazine-6,8-dione (50 mg, 0.087 mmol) in CC14 (10 mL) and DMF (0.2 mL) was added NBS (31 mg). Then the mixture was stirred at r.t. overnight, washed with water and dried over Na2SO4. The organic phase was removed solvent and the residue was purified by Prep-HPLC to afford compound 15 (20 mg, yield 35.3%) as a light yellow solid.
Combined with another batch, total 65mg of compound 15 as obtained. 1H-NMR (400 MHz, CDC13):
67.62-7.60 (m, 4H), 7.52 (s, 1H), 7.39-7.36 (m, 9H), 7.32-7.04 (m, 5H), 6.99-6.96 (m, 1H), 6.82-6.77 (m, 1H), 6.70-6.67 (m, 1H), 6.39-6.37 (d, J= 7.6 Hz, 1H), 6.13-6.09 (m, 1H), 5.69-5.60 (m, 2H), 4.46-5.40 (m, 2H), 5.23-5.18 (m, 3H), 5.02 (s, 1H), 4.70-4.62 (m, 2H), 4.50-4.35 (m, 2H), 4.09-3.71 (m, 6H), 3.43-3.23 (m, 4H), 2.95-2.72 (m, 2H). LCMS
[mobile phase: from 60% water (0.1% TFA) and 40% acetonitrile to 50% water (0.1% TFA) and 50%
acetonitrile in 6 min, finally under these conditions for 0.5 min.] purity is >96%, Rt = 3.385 min; MS Calcd.: 651, 653; MS Found: 652, 654 (M+1+).
Example 6 12-(7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-y1)-9-(dimethylphosphory1)-7-hydroxy-3,4,12,12a-tetrahydro-1H41,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (E-la and E-1b) OBn 0 OBn 0 OH 0 N,No .PH
¨ LiCI, NMP
Br 15 16a, 16b E-la, E-lb
Combined with another batch, total 65mg of compound 15 as obtained. 1H-NMR (400 MHz, CDC13):
67.62-7.60 (m, 4H), 7.52 (s, 1H), 7.39-7.36 (m, 9H), 7.32-7.04 (m, 5H), 6.99-6.96 (m, 1H), 6.82-6.77 (m, 1H), 6.70-6.67 (m, 1H), 6.39-6.37 (d, J= 7.6 Hz, 1H), 6.13-6.09 (m, 1H), 5.69-5.60 (m, 2H), 4.46-5.40 (m, 2H), 5.23-5.18 (m, 3H), 5.02 (s, 1H), 4.70-4.62 (m, 2H), 4.50-4.35 (m, 2H), 4.09-3.71 (m, 6H), 3.43-3.23 (m, 4H), 2.95-2.72 (m, 2H). LCMS
[mobile phase: from 60% water (0.1% TFA) and 40% acetonitrile to 50% water (0.1% TFA) and 50%
acetonitrile in 6 min, finally under these conditions for 0.5 min.] purity is >96%, Rt = 3.385 min; MS Calcd.: 651, 653; MS Found: 652, 654 (M+1+).
Example 6 12-(7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-y1)-9-(dimethylphosphory1)-7-hydroxy-3,4,12,12a-tetrahydro-1H41,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (E-la and E-1b) OBn 0 OBn 0 OH 0 N,No .PH
¨ LiCI, NMP
Br 15 16a, 16b E-la, E-lb
[0128] Step 1: 7-(benzyloxy)-12-(7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-3,4,12,12a-tetrahydro-1H-[1,41oxazino[3,4-c1pyrido[2,1-f][1,2,41triazine-6,8-dione (16a and 16 b)
[0129] To a tube was added a solution of compound 15 (46 mg, 0.071 mmol) in 1, dioxane (8 mL), Cs2CO3 (205 mg, 0.63 mmol), dimethyl phosphine oxide (112 mg, 1.42 mmol), KI (60 mg, 0.36 mmol), Pd(OAc)2 (24 mg, 0.107 mmol) and Xantphos (88 mg, 0.152 mmol), and the mixture was bubbled with N2 for 3 min. The tube was sealed and the mixture was under microwave reacted at 95 C for 3h. The reaction was concentrated and added water (10 mL), extracted with EA (10 mL*3), purified by Prep-TLC (PE: EA=1:2) to obtain compound 16a (5 mg, yield 10.9%) and compound 16b (10 mg, yield 21.8%) as a yellow solid. MS Calcd: 649; MS Found: 650 ([M + H1+). In this Example, when the mixture of stereoisomers are separated by HPLC, the first-eluting mixture was labeled "16a," and the second-eluting mixture was labeled "16b." 16a and 16b each are a mixture of two diastereomers.
[0130] Step 2: Synthesis of 12-(7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,41triazine-6,8-dione (E-la and E-1b)
[0131] To a solution of 16a (5 mg, 0.0077 mmol) in NMP (1.5 mL) was added LiC1 (7.2 mg, 0.17 mmol) and the reaction was stirred at 80 C overnight and directly purified by Prep-HPLC (0.1% TFA) to afford compound E-la (2.7 mg, yield 52.1%) as a white solid. 1H-NMR (400 MHz, Me0H-d4): 6 7.41 - 7.39 (d, J= 7.2 Hz, 1H), 7.28 - 7.12 (m, 4H), 7.00 ¨
6.94 (m, 1H), 6.79-6.76 (m, 1H), 5.45 (s, 1H), 5.44-5.26 (dd, J= 2 Hz, 1H), 4.49-4.34 (m, 3H), 4.07-4.03 (d, J= 14.8 Hz, 1H), 3.96-3.92 (dd, J= 2.8 Hz, 1H), 3.68- 3.54 (m, 2H), 3.41-3.38 (m, 1H), 2.82-2.75 (m, 1H) , 1.56-1.52 (d, J= 14.4 Hz, 3H), 1.40-1.36 (d, J= 14 Hz, 3H). LCMS [mobile phase: from 95% water (0.1% TFA) and 5% acetonitrile to 5% water (0.1% TFA) and 95% acetonitrile in 6 min, finally under these conditions for 0.5 min.] purity is >97%, Rt = 3.567 min; MS Calcd.: 559; MS Found: 560 ([M+1]+).
6.94 (m, 1H), 6.79-6.76 (m, 1H), 5.45 (s, 1H), 5.44-5.26 (dd, J= 2 Hz, 1H), 4.49-4.34 (m, 3H), 4.07-4.03 (d, J= 14.8 Hz, 1H), 3.96-3.92 (dd, J= 2.8 Hz, 1H), 3.68- 3.54 (m, 2H), 3.41-3.38 (m, 1H), 2.82-2.75 (m, 1H) , 1.56-1.52 (d, J= 14.4 Hz, 3H), 1.40-1.36 (d, J= 14 Hz, 3H). LCMS [mobile phase: from 95% water (0.1% TFA) and 5% acetonitrile to 5% water (0.1% TFA) and 95% acetonitrile in 6 min, finally under these conditions for 0.5 min.] purity is >97%, Rt = 3.567 min; MS Calcd.: 559; MS Found: 560 ([M+1]+).
[0132] To a solution of compound 16b (10 mg, 0.015 mmol) in NMP (1.5 mL) was added LiC1 (7.2 mg, 0.17 mmol) and the reaction was stirred at 80 C overnight and directly purified by Prep-HPLC (0.1% TFA) to afford compound E-lb (4.4 mg, yield 43.6%) as a white solid.
1-1-1-NMR (400 MHz, Me0H-d4): 6 7.73- 7.70 (d, J= 10.4 Hz, 1H), 7.33- 7.19(m, 4H), 6.93 ¨6.86 (m, 2H), 5.67 (s, 1H), 5.51-5.47 (dd, J= 2.4 Hz, 1H), 4.72-4.63 (m, 3H), 4.16-4.13 (d, J= 14 Hz, 1H), 4.11-4.04 (m, 1H), 3.81- 3.70 (m, 2H), 3.54-3.47 (m, 1H), 3.18-3.11 (m, 1H) , 1.66-1.63 (d, J= 14.4 Hz, 3H), 1.46-1.42 (d, J= 14 Hz, 3H). MS Calcd:
559; MS
Found: 560 ([M + Hr). LCMS [mobile phase: from 80% water (0.1% TFA) and 20%
acetonitrile to 30% water (0.1% TFA) and 70% acetonitrile in 6 min, finally under these conditions for 0.5 min.] purity is >98%, Rt = 3.271 min; MS Calcd.: 559; MS
Found: 560 ([M+1]+).
1-1-1-NMR (400 MHz, Me0H-d4): 6 7.73- 7.70 (d, J= 10.4 Hz, 1H), 7.33- 7.19(m, 4H), 6.93 ¨6.86 (m, 2H), 5.67 (s, 1H), 5.51-5.47 (dd, J= 2.4 Hz, 1H), 4.72-4.63 (m, 3H), 4.16-4.13 (d, J= 14 Hz, 1H), 4.11-4.04 (m, 1H), 3.81- 3.70 (m, 2H), 3.54-3.47 (m, 1H), 3.18-3.11 (m, 1H) , 1.66-1.63 (d, J= 14.4 Hz, 3H), 1.46-1.42 (d, J= 14 Hz, 3H). MS Calcd:
559; MS
Found: 560 ([M + Hr). LCMS [mobile phase: from 80% water (0.1% TFA) and 20%
acetonitrile to 30% water (0.1% TFA) and 70% acetonitrile in 6 min, finally under these conditions for 0.5 min.] purity is >98%, Rt = 3.271 min; MS Calcd.: 559; MS
Found: 560 ([M+1]+).
[0133] Similar to 16a and 16b, E-la and E-lb each are a mixture of two diastereomers.
Example 7 Synthesis of (R)-12-((S)-7,8-difitioro-6,11-dihydrodibenzo[b,e]thiepin-11-y1)-(dimethylphosphory1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-11,41oxazino[3,4-c]pyrido[2,1-.1][1, 2,41triazine-6,8-dione (E-1c) NBS
*LN LiCI, NMP N)C1 _____________________________________________________ - Br 1 Step1 Brr\j'NO Step 2 17 18 I Step OH 0 OBn 0 OBn 0 ON ON
ON,) Li CI, NMP pNNOMe2P(0)H Br N 0'l ¨
_________________________ 0-1 Step 5 PdC12dppf, Et3N, MeCN, 90 C F
Step 4 E-1-c F 21 20
Example 7 Synthesis of (R)-12-((S)-7,8-difitioro-6,11-dihydrodibenzo[b,e]thiepin-11-y1)-(dimethylphosphory1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-11,41oxazino[3,4-c]pyrido[2,1-.1][1, 2,41triazine-6,8-dione (E-1c) NBS
*LN LiCI, NMP N)C1 _____________________________________________________ - Br 1 Step1 Brr\j'NO Step 2 17 18 I Step OH 0 OBn 0 OBn 0 ON ON
ON,) Li CI, NMP pNNOMe2P(0)H Br N 0'l ¨
_________________________ 0-1 Step 5 PdC12dppf, Et3N, MeCN, 90 C F
Step 4 E-1-c F 21 20
[0134] Step 1. Synthesis of (((R)-9-bromo-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (18)
[0135] To a solution of compound 17 (6 g, 10.5 mmol, commercially available) in DMF
(30 mL) was added NBS (2.8 g, 15.7 mmol), then the reaction mixture was stirred at room temperature overnight. To the reaction mixturewas added water (120 mL), and the reaction mixture was filtered and the obtained cake was washed with water, dried in vacuum to afford compound 18 (7.1 g, yield 100%) as a light yellow solid, which was directly used in the next step without further purification. MS Calcd: 649; MS Found: 650 ([M+H]+).
(30 mL) was added NBS (2.8 g, 15.7 mmol), then the reaction mixture was stirred at room temperature overnight. To the reaction mixturewas added water (120 mL), and the reaction mixture was filtered and the obtained cake was washed with water, dried in vacuum to afford compound 18 (7.1 g, yield 100%) as a light yellow solid, which was directly used in the next step without further purification. MS Calcd: 649; MS Found: 650 ([M+H]+).
[0136] Step 2. Synthesis of (R)-9-bromo-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (19)
[0137] To a suspension of compound 18 (6.0 g, 9.2 mmol) in NMP (36 mL) was added LiC1 (3.8 g, 92 mmol), then the reaction mixture was stirred at 80 C
overnight. The reaction mixture was diluted with EA (50 mL), washed with water, brine, dried over Na2SO4, and filtered. The filtrate was evaporated to afford crude compound 19 (5.2 g) as a pale solid, which was directly used in next step without further purification. MS Calcd:
560; MS Found:
561 ([M+1-11+).
overnight. The reaction mixture was diluted with EA (50 mL), washed with water, brine, dried over Na2SO4, and filtered. The filtrate was evaporated to afford crude compound 19 (5.2 g) as a pale solid, which was directly used in next step without further purification. MS Calcd:
560; MS Found:
561 ([M+1-11+).
[0138] Step 3. Synthesis of (R)-7-(benzyloxy)-9-bromo-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-3,4,12,12a-tetrahydro-1H41,41oxazino[3,4-clpyrido[2,1-f][1,2,41triazine-6,8-dione (20)
[0139] To a solution of compound 19 (5.2 g, 9.2 mmol) in DMA (50 mL) was added K2CO3 (2.54 g, 18.4 mmol), KI (1.53 g, 9.2 mmol), BnBr (3.15 g, 18.4 mmol), then the reaction mixture was stirred at 50 C overnight. The reaction mixture was diluted with EA
(50 mL), washed with water, brine, purified by Prep-HPLC to afford compound 20 (4.9 g, 81.8%) as alight yellow solid. MS Calcd: 651; MS Found: 652 ([M+Hl+).
(50 mL), washed with water, brine, purified by Prep-HPLC to afford compound 20 (4.9 g, 81.8%) as alight yellow solid. MS Calcd: 651; MS Found: 652 ([M+Hl+).
[0140] Step 4. Synthesis of (R)-7-(benzyloxy)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-3,4,12,12a-tetrahydro-[1,41oxazino[3,4-clpyrido[2,1-f][1,2,41triazine-6,8-dione (21)
[0141] To a solution of compound 20 (2.0 g, 3.07 mmol) in MeCN (90 mL) was added dimethylphosphine oxide (2.78 g, 35.6 mmol), TEA (2.2 g, 21.8 mmol), Pd(dppf)C12 (500 mg), and the reaction was filled with N2 for 3 times. Under N2, the reaction mixture was stirred at 90 C for 20 h. Cooled to rt, the reaction mixture was evaporated to dryness and diluted with water, extracted with EA (50 mL *3), dried over Na2SO4and evaporated. The obtained reaction mixture was purified by flash column chromatography on silica gel (DCM:Me0H=10:1) to afford compound 21 (1.8 g, yield 90 %) as a yellow solid.
MS Calcd:
649; MS Found: 650 ([M+Hl+).
MS Calcd:
649; MS Found: 650 ([M+Hl+).
[0142] Step 5. Synthesis of (R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,41oxazino[3,4-clpyrido[2,1-f][1,2,41triazine-6,8-dione (E-1c)
[0143] To a suspension of compound 21 (2 g, 3 mmol) in NMP (7 mL) was added LiC1 (1.3 g, 30 mmol), then the reaction mixture was stirred at 80 C overnight. The reaction was purified by Prep-HPLC (0.1%TFA) to afford compound E-lc (1.1 g, 63.8%) as an off white solid. 11-I-NMR (400 MHz, DMSO-d6): 6 7.47-7.39 (m, 3H), 7.18-7.14 (m, 1H), 7.10-7.08 (m, 1H), 6.99-6.97 (m, 1H), 6.87-6.83 (m, 1H), 5.80 (s, 1H), 5.43-5.39 (dd, J=
2.4 Hz and 14 Hz, 1H), 4.59-4.55 (dd, J= 2.8 Hz and 10 Hz, 1H), 4.46-4.42 (m, 1H), 4.11-4.01 (m, 2H)), 3.77- 3.67 (m, 2H), 3.47-3.41 (m, 1H), 3.10-3.03 (m, 1H), 1.46-1.43 (d, J=
14.4 Hz, 3H), 1.23-1.19 (d, J= 14.4 Hz, 3H). LCMS [mobile phase: from 80% water (0.1% TFA) and 20%
acetonitrile to 30% water (0.1% TFA) and 70% acetonitrile in 6 min, finally under these conditions for 0.5 min.] purity is >98%, Rt = 3.184 min; MS Calcd.: 559; MS
Found: 560 ([M+1]+).
Synthesis of compounds E-2 to E-10
2.4 Hz and 14 Hz, 1H), 4.59-4.55 (dd, J= 2.8 Hz and 10 Hz, 1H), 4.46-4.42 (m, 1H), 4.11-4.01 (m, 2H)), 3.77- 3.67 (m, 2H), 3.47-3.41 (m, 1H), 3.10-3.03 (m, 1H), 1.46-1.43 (d, J=
14.4 Hz, 3H), 1.23-1.19 (d, J= 14.4 Hz, 3H). LCMS [mobile phase: from 80% water (0.1% TFA) and 20%
acetonitrile to 30% water (0.1% TFA) and 70% acetonitrile in 6 min, finally under these conditions for 0.5 min.] purity is >98%, Rt = 3.184 min; MS Calcd.: 559; MS
Found: 560 ([M+1]+).
Synthesis of compounds E-2 to E-10
[0144] Compounds E-2 to E-10 are obtained according to the following condition: To an aqueous (1.0 mL) suspension of compound E-lc (0.10 mmol) and potassium carbonate (138 mg, 0.22 mmol) are added tetrabutylammonium hydrogen sulfate (34 mg, 0.10 mmol) and dichloromethane (0.5 mL), and the mixture is stirred at room temperature for 10 minutes. To the reaction solution is added a dichloromethane (0.5 mL) solution of corresponding iodide (0.22 mmol), and the mixture is further stirred for 2 hours. Thereafter, to the reaction solution is added water, the dichloromethane layer is separated, and the aqueous layer is extracted with dichloromethane once. The combined extracts are washed with brine and then dried over sodium sulfate. The solvent is concentrated and the residue is purified by silica gel column chromatography.
(21)( 0 )L00 0 00 0 (21).L00 *(N 0)Y.N 0*LN1 pr\I,N),0 pN,N)-.NO MDN,,,,)0 O'i 0--1 -_ 0' I 171 F F F
S S S
F F
F
)...,0 000 0 AO 0 (D).L00 0 )YLN **LN IY.LN
P N,N -P).N..0 N,N P
)-µ0 N,N)-.N.0 0": 0--_ F F F
S S S
F F F
(si)L00 0 0 0 0 i)L00 0 N NH2 0*-LN NH2 0*Lre Th mr\I.N),N.0 pN,N)-N.0 P r\I.N).N.0 -(21-1 - 0-1 - _ 0-1 F F F
S S S
F F F
(21)( 0 )L00 0 00 0 (21).L00 *(N 0)Y.N 0*LN1 pr\I,N),0 pN,N)-.NO MDN,,,,)0 O'i 0--1 -_ 0' I 171 F F F
S S S
F F
F
)...,0 000 0 AO 0 (D).L00 0 )YLN **LN IY.LN
P N,N -P).N..0 N,N P
)-µ0 N,N)-.N.0 0": 0--_ F F F
S S S
F F F
(si)L00 0 0 0 0 i)L00 0 N NH2 0*-LN NH2 0*Lre Th mr\I.N),N.0 pN,N)-N.0 P r\I.N).N.0 -(21-1 - 0-1 - _ 0-1 F F F
S S S
F F F
[0145] In some embodiments, provided herein is a compound selected from the group consisting of:
(((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-11,41oxazino[3,4-clpyrido[2,1-f][1,2,41triazin-7-y0oxy)methyl ethyl carbonate (E-2), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-11,41oxazino[3,4-clpyrido[2,1-f][1,2,41triazin-7-y0oxy)methyl methyl carbonate (E-3), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-clpyrido[2,14][1,2,41triazin-7-y0oxy)methyl acetate (E-4), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-clpyrido[2,14][1,2,41triazin-7-y0oxy)methyl isopropyl carbonate (E-5), (R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-clpyrido[2,14][1,2,41triazin-7-y1 acetate (E-6), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-clpyrido[2,14][1,2,41triazin-7-y0oxy)methyl (2-methoxyethyl) carbonate (E-7), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-clpyrido[2,14][1,2,41triazin-7-y0oxy)methyl L-valinate (E-8), 1-(((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-c1pyrido[2,14][1,2,41triazin-7-y0oxy)ethyl L-valinate (E-9), and (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-clpyrido[2,14][1,2,41triazin-7-y0oxy)methyl L-leucinate (E-10).
Example 8 Synthesis of (R)-9-(diethylphosphory1)-124(S)-7,8-difitioro-6, 11-dihydrodibenzo[b,e]-thiepin-11-y1)-7-hydroxy-3,4, 12,12a-tetrahydro-1H-11,41oxazino[3,4-o]pyrido[2,1-.1][1, 2,41triazine-6,8-dione (F-1) OBn 0 OBn 0 OH 0 0*.(N Oy=LN
BrN
Et2P(0)H
LiCI, NMP Et, N
PdC12dppf, Et3N, 0' I
Et MeCN, 90 C
(((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-11,41oxazino[3,4-clpyrido[2,1-f][1,2,41triazin-7-y0oxy)methyl ethyl carbonate (E-2), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-11,41oxazino[3,4-clpyrido[2,1-f][1,2,41triazin-7-y0oxy)methyl methyl carbonate (E-3), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-clpyrido[2,14][1,2,41triazin-7-y0oxy)methyl acetate (E-4), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-clpyrido[2,14][1,2,41triazin-7-y0oxy)methyl isopropyl carbonate (E-5), (R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-clpyrido[2,14][1,2,41triazin-7-y1 acetate (E-6), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-clpyrido[2,14][1,2,41triazin-7-y0oxy)methyl (2-methoxyethyl) carbonate (E-7), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-clpyrido[2,14][1,2,41triazin-7-y0oxy)methyl L-valinate (E-8), 1-(((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-c1pyrido[2,14][1,2,41triazin-7-y0oxy)ethyl L-valinate (E-9), and (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-clpyrido[2,14][1,2,41triazin-7-y0oxy)methyl L-leucinate (E-10).
Example 8 Synthesis of (R)-9-(diethylphosphory1)-124(S)-7,8-difitioro-6, 11-dihydrodibenzo[b,e]-thiepin-11-y1)-7-hydroxy-3,4, 12,12a-tetrahydro-1H-11,41oxazino[3,4-o]pyrido[2,1-.1][1, 2,41triazine-6,8-dione (F-1) OBn 0 OBn 0 OH 0 0*.(N Oy=LN
BrN
Et2P(0)H
LiCI, NMP Et, N
PdC12dppf, Et3N, 0' I
Et MeCN, 90 C
[0146] Step 1: To a solution of compound 20 (200 mg, 0.307 mmol) in MeCN (9 mL) was added diethylphosphine oxide (390 mg, 3.68 mmol), TEA (220 mg, 2.18 mmol), Pd(dppf)C12 (60 mg), filled with N2 for 3 times. Under N2, the reaction was stirred at 90 C for 20 h.
Cooled to rt, the mixture was evaporated to dryness and diluted with water, extracted with EA (5 mL *3), dried over Na2SO4and evaporated. The crude was purified by flash column chromatography on silica gel (DCM:Me0H=10:1) to afford compound 22 (150 mg, yield 72.1%) as a yellow solid. MS Calcd: 677; MS Found: 678 ([M+H]+).
Cooled to rt, the mixture was evaporated to dryness and diluted with water, extracted with EA (5 mL *3), dried over Na2SO4and evaporated. The crude was purified by flash column chromatography on silica gel (DCM:Me0H=10:1) to afford compound 22 (150 mg, yield 72.1%) as a yellow solid. MS Calcd: 677; MS Found: 678 ([M+H]+).
[0147] Step 2: To a suspension of compound 22 (150 mg, 0.22 mmol) in NMP (1 mL) was added LiC1 (93 mg, 2.2 mmol), then stirred at 80 C overnight. The reaction was directly purified by Prep-HPLC (0.1%TFA) to afford compound F-1 (77 mg, 59.2%) as a white solid.
1H-NMR (400 MHz, DMSO-d6): 6 7.50-7.47 (d, J= 9.6 Hz, 3H), 7.42-7.39 (m, 2H), 7.11-7.08 (m, 2H), 7.03-7.02 (m, 1H), 6.88-6.84 (m, 1H), 5.82 (s, 1H), 5.39-5.35 (m, 1H), 4.59-4.55 (dd, J= 2.8 Hz and 9.6 Hz, 1H), 4.45-4.42 (m, 1H), 4.12-4.04 (m, 2H), 3.72-3.66 (m, 2H), 3.49-3.42 (m, 1H), 3.09-3.02 (m, 1H), 1.79-1.70 (m, 2H), 1.65-1.42 (m, 2H), 0.87-0.79 (m, 3H), 0.70-0.62 (m, 3H). LCMS [mobile phase: from 70% water (0.1% TFA) and 30% acetonitrile to 40% water (0.1% TFA) and 60% acetonitrile in 6 min, finally under these conditions for 0.5 min.] purity is > 99%, Rt = 2.864 min; MS Calcd.: 587; MS
Found: 588 ([M+1]+).
Biological Examples
1H-NMR (400 MHz, DMSO-d6): 6 7.50-7.47 (d, J= 9.6 Hz, 3H), 7.42-7.39 (m, 2H), 7.11-7.08 (m, 2H), 7.03-7.02 (m, 1H), 6.88-6.84 (m, 1H), 5.82 (s, 1H), 5.39-5.35 (m, 1H), 4.59-4.55 (dd, J= 2.8 Hz and 9.6 Hz, 1H), 4.45-4.42 (m, 1H), 4.12-4.04 (m, 2H), 3.72-3.66 (m, 2H), 3.49-3.42 (m, 1H), 3.09-3.02 (m, 1H), 1.79-1.70 (m, 2H), 1.65-1.42 (m, 2H), 0.87-0.79 (m, 3H), 0.70-0.62 (m, 3H). LCMS [mobile phase: from 70% water (0.1% TFA) and 30% acetonitrile to 40% water (0.1% TFA) and 60% acetonitrile in 6 min, finally under these conditions for 0.5 min.] purity is > 99%, Rt = 2.864 min; MS Calcd.: 587; MS
Found: 588 ([M+1]+).
Biological Examples
[0148] The activity of a compound according to the present invention can be assessed by the following in vitro and in vivo methods.
Example 9
Example 9
[0149] Using the test assays described herein, representative compounds of the invention are tested by in vitro assays.
Influenza virus Cap-Dependent Endonuclease (CEN) inhibition assay
Influenza virus Cap-Dependent Endonuclease (CEN) inhibition assay
[0150] Prepared assay buffer 2 solution (20 mM Tris, 150 mM NaCl, 2 mM MnC12, 10 mM
P-Mercaptoethanol, 0.2% Trition-X100, pH7.9), 6 x compound working solution, and 100 nM of Influenza Virus CEN PAn enzyme working solution (2X). Added 9 pL of enzyme working solution to each well of 384-well plate (Corning, 3676), then added 3 pt of 6 x compound working solution to the indicated well of the 384-well plate, centrifuged at 200 g, RT for 60s, then incubated the plate at 25 C for 20min. The results are shown below in Table 1.
P-Mercaptoethanol, 0.2% Trition-X100, pH7.9), 6 x compound working solution, and 100 nM of Influenza Virus CEN PAn enzyme working solution (2X). Added 9 pL of enzyme working solution to each well of 384-well plate (Corning, 3676), then added 3 pt of 6 x compound working solution to the indicated well of the 384-well plate, centrifuged at 200 g, RT for 60s, then incubated the plate at 25 C for 20min. The results are shown below in Table 1.
[0151] The following procedures should be protected from light:
Prepared 600 nM of influenza PA ssDNA substrate _2 working solution (3X).
Added 6 pL of 3X substrate working solution to each well of the 384-well plate to start the reaction at 37 C and incubated for 4hr.
Collected the data by Victor Nivo microplate reader at Ex/Em = 485 nm/535 nm.
Prepared 600 nM of influenza PA ssDNA substrate _2 working solution (3X).
Added 6 pL of 3X substrate working solution to each well of the 384-well plate to start the reaction at 37 C and incubated for 4hr.
Collected the data by Victor Nivo microplate reader at Ex/Em = 485 nm/535 nm.
[0152] Data Analysis was conducted as follows:
Z' factor = 1-3*(SDmax+SDmin)/(Meanmax-Meanmin ) CVmax = (SDmax/Meanmax)*100%
CVmm = (SDmin/Meanmm)*100%
S/B = Singal/Background Vehicle Control (Max): 0.1% DMSO
Positive Control (Min): 1,000nM of Baloxavir acid Calculation Equation for IC50Value:
Y=Bottom + (Top-Bottom)/(1+10^((LogIC50-X)*HillSlope)) X: log value of compound; Y: Inhibition%
Z' factor = 1-3*(SDmax+SDmin)/(Meanmax-Meanmin ) CVmax = (SDmax/Meanmax)*100%
CVmm = (SDmin/Meanmm)*100%
S/B = Singal/Background Vehicle Control (Max): 0.1% DMSO
Positive Control (Min): 1,000nM of Baloxavir acid Calculation Equation for IC50Value:
Y=Bottom + (Top-Bottom)/(1+10^((LogIC50-X)*HillSlope)) X: log value of compound; Y: Inhibition%
[0153] As listed in Table 1, representative compounds (except prodrug C-1) showed potent inhibitory effect on the cap dependent endonuclease activity.
Table 1. Inhibitory potency on the enzymatic activity of cap dependent endonuclease Index Compound CEN ICso (nM) 1 Baloxavir acid 14 4 E-1 a 31 E-lb 32 In vitro antiviral activity
Table 1. Inhibitory potency on the enzymatic activity of cap dependent endonuclease Index Compound CEN ICso (nM) 1 Baloxavir acid 14 4 E-1 a 31 E-lb 32 In vitro antiviral activity
[0154] MDCK cells were seeded in 96 well plates at a density of 15,000 cells/well and cultured at 37 C and 5% CO2 overnight. Next day, serially diluted compounds and viruses were added in to cells. The resulting cultures were kept at 35 C or 37 C and 5% CO2 for additional 5 days until virus infection in the virus control (cells infected with virus, without compound treatment) display significant cytopathic effect (CPE). Antiviral activity of the compounds was calculated based on the protection of the virus-induced CPE at each concentration normalized by the virus control.
[0155] Cytotoxicity of the compounds was assessed under the same conditions, but without virus infection, in parallel. Cell viability was measured with CCK8 following the manufacturer's manual.
[0156] Antiviral activity and cytotoxicity of the compounds are expressed as %
Inhibition and % Viability, respectively, and calculated with the formulas below:
Inhibition (%) = (Raw datacpp - Averagevc) / (Averagecc - Averagevc)* 100 Viability (%) = (Raw datacpp - Averagemc) / (Averagecc - Averagemc)*100
Inhibition and % Viability, respectively, and calculated with the formulas below:
Inhibition (%) = (Raw datacpp - Averagevc) / (Averagecc - Averagevc)* 100 Viability (%) = (Raw datacpp - Averagemc) / (Averagecc - Averagemc)*100
[0157] Raw datacm indicates the values of the sample-treated wells; Averagevc, Averagecc and Averagemc indicate the average values of the virus control, cell control (cells without virus infection or compound treatment) and medium control (medium only) wells, respectively.
[0158] ECso and CC50 values were calculated using the GraphPad Prism software with equation "log(inhibitor) vs. response -- Variable slope". Data are listed in Table 2.
Representative compounds, in particular, B-1 showed potent antivirus activity and little cytotoxicity.
Table 2. In vitro antivirus activity and cytotoxicity Baloxavir Oseltamivir B-1 E- 1 c F-1 acid acid IFV A/PR/8/34 (H1N1) 1.1 68 >100 0.73 >100,000 IFV A/WSN/33 (H1N1) 0.32 58 57 0.44 >100,000 EC5() A/Weiss/43 (H1N1) 1.2 133 22 0.74 476 (nM) Oseltamivir-resistant 1.1 254 881 1.0 >100,000 A/Weiss/43 (H1N1) A/California/07/2009 (H1N1)pdm09 0.37 129 125 0.66 231 Si A/Hongkong/8/68 0.68 207 310 1.7 20 (H3N2) B/Florida/78/2015 25 >1000 >1000 16 8481 B/Lee/40 12 >1000 >1000 6.3 CC50 (pM) 13 >100 >100 12 >100 Example 10 In vivo antiviral activity
Representative compounds, in particular, B-1 showed potent antivirus activity and little cytotoxicity.
Table 2. In vitro antivirus activity and cytotoxicity Baloxavir Oseltamivir B-1 E- 1 c F-1 acid acid IFV A/PR/8/34 (H1N1) 1.1 68 >100 0.73 >100,000 IFV A/WSN/33 (H1N1) 0.32 58 57 0.44 >100,000 EC5() A/Weiss/43 (H1N1) 1.2 133 22 0.74 476 (nM) Oseltamivir-resistant 1.1 254 881 1.0 >100,000 A/Weiss/43 (H1N1) A/California/07/2009 (H1N1)pdm09 0.37 129 125 0.66 231 Si A/Hongkong/8/68 0.68 207 310 1.7 20 (H3N2) B/Florida/78/2015 25 >1000 >1000 16 8481 B/Lee/40 12 >1000 >1000 6.3 CC50 (pM) 13 >100 >100 12 >100 Example 10 In vivo antiviral activity
[0159] Balb/c mice of 6-8 week old were used in this study. The influenza virus PR/8/34 diluent was pipetted by a pipette and inoculated via intranasal route at the amount of 1,000 PFU in 50 pL/animal after animals were deeply anesthetized on the day of inoculation (day 0). B-1 dosing solutions were prepared in 5%DMS0/40%PEG400 /55%water at 0.5 mg/mL.
C-1 dosing solutions were prepared in 5%DMS0/40%PEG400 /55%water at 0.15 mg/mL
and 0.5 mg/mL. Oseltamivir Phosphate dosing solutions were prepared in PBS X1 at 1 mg/ml. The vehicle was 5%DMS0/40%PEG400 /55%water solution. B-1, C-1, Oseltamivir Phosphate or vehicle was administered via PO route following the regimen of BID (8/16 h) from day 1 to day 7 at 10 mL/kg/day, with first dose given at 24 hours post virus inoculation.
Animal body weight and survival were continuously monitored from day 0 to day 14.
Animals that lose more than 35 percent of their body weight will be euthanized and included into the death number. The body weight and survival rate of the animals were statistically analyzed to evaluate the in vivo efficacy of B-1, C-1, Oseltamivir Phosphate and vehicle in the influenza mouse infection model. The results were summarized in Figure 1A
and Figure 1B.
C-1 dosing solutions were prepared in 5%DMS0/40%PEG400 /55%water at 0.15 mg/mL
and 0.5 mg/mL. Oseltamivir Phosphate dosing solutions were prepared in PBS X1 at 1 mg/ml. The vehicle was 5%DMS0/40%PEG400 /55%water solution. B-1, C-1, Oseltamivir Phosphate or vehicle was administered via PO route following the regimen of BID (8/16 h) from day 1 to day 7 at 10 mL/kg/day, with first dose given at 24 hours post virus inoculation.
Animal body weight and survival were continuously monitored from day 0 to day 14.
Animals that lose more than 35 percent of their body weight will be euthanized and included into the death number. The body weight and survival rate of the animals were statistically analyzed to evaluate the in vivo efficacy of B-1, C-1, Oseltamivir Phosphate and vehicle in the influenza mouse infection model. The results were summarized in Figure 1A
and Figure 1B.
[0160] For the vehicle group, infection of influenza virus PR/8/34 produced substantial body weight loss and all the mice died on Day 8. Treatment of C-1 resulted in significant dose-dependent improvement in body weight loss. The body weight loss at 5 mg/kg of C-1 treatment was minimal. Similarly, treatment of B-1 at 5 mg/kg also showed potent antivirus efficacy with minimal body weight loss. All the mice in the groups of B-1 and C-1 treatment survived throughout the study. Treatment of oseltamivir did not result in substantial improvement in body weight loss and 60% mice died.
Example 11
Example 11
[0161] The study of drug metabolism and pharmacokinetics of representative compounds was conducted.
Liver microsomal stability
Liver microsomal stability
[0162] Liver microsomal assay was used to evaluate the metabolic stability of A-1-P2. A-1-P2 at the concentration of 1 M was incubated with 0.5 mg/mL liver microsome in the presence of NADPH and UDPGA as the co-factors for 0, 15, 30, 45 and 60 minutes. The incubation was carried out at 37 C with 5% CO2 and saturating humidity.
Disappearance of the compound was monitored by LC/MS/MS and t112 and intrinsic clearance were calculated from the disappearance of the compound. In certain embodiments, the determined till and intrinsic clearance of A-1-P2 in different species is described herein in Table 3.
Table 3. Liver microsome stability of A-1-P2 Intrinsic clearance Crint, Species Half-life till (min) ( L/min/mg protein) Human 3655 2.2 Cynomolgus 85 16 Dog 375 4.5 Rat 173 8.3 Mice 286 5.2 Pharmacokinetics in rats
Disappearance of the compound was monitored by LC/MS/MS and t112 and intrinsic clearance were calculated from the disappearance of the compound. In certain embodiments, the determined till and intrinsic clearance of A-1-P2 in different species is described herein in Table 3.
Table 3. Liver microsome stability of A-1-P2 Intrinsic clearance Crint, Species Half-life till (min) ( L/min/mg protein) Human 3655 2.2 Cynomolgus 85 16 Dog 375 4.5 Rat 173 8.3 Mice 286 5.2 Pharmacokinetics in rats
[0163] B-1 was administered to non-fasted male SD rats (6-8 weeks old, 200-300 grams, 3 animals each group) via intravenous (IV) bolus at 0.25 mg/kg and by oral gavage (PO) at 3 mg/kg. C-1 was administered to 3 non-fasted male SD rats via oral gavage at 3 mg/kg. Blood samples (-0.2 mL each time point) were collected via the jugular vein into tubes containing potassium ethylenediaminetetraacetic acid (K2EDTA) as the anticoagulant at 0.033, 0.083, 0.25, 0.5, 1, 2, 4, 8 and 24 hours post dose for IV administration and 0.083, 0.25, 0.5, 1, 2, 4, 8 and 24 hours post dose for PO administration. The blood samples were then centrifuged for minutes in a centrifuge refrigerated at 4 C. The resultant plasma samples were analyzed using LC/MS/MS to determine concentrations of B-1. Non-compartmental model with WinNonlin (Phoenix, version 8.0) software was used to calculate pharmacokinetic (PK) parameters. The PK results are listed in Table 4. The oral bioavailability of B-1 following oral gavage administration of B-1 in rats is 14%; and the oral bioavailability of B-1 following oral gavage administration of the prodrug C-1 is 30%. In contrast, the oral bioavailability of baloxavir in rats is 0.69% following oral administration of baloxavir, and the oral bioavailability of baloxavir in rats is 9.8-14.7% following administration of its prodrug baloxavir marboxil (Baloxavir marboxil NDA document).
Table 4. PK parameters in SD rats Unit IV 0.25mg/kg PO 3mg/kg PO 3mg/kg n=3 n=3 n=3 t1/2 h 4.0 3.1 3.5 Tmaxh 2.6 1.7 Cmax ng/mL 21 37 AUCiast h*ng/mg 84 123 280 AUCInf h*ng/mL 92 149 289 Pharmacokinetics in mice
Table 4. PK parameters in SD rats Unit IV 0.25mg/kg PO 3mg/kg PO 3mg/kg n=3 n=3 n=3 t1/2 h 4.0 3.1 3.5 Tmaxh 2.6 1.7 Cmax ng/mL 21 37 AUCiast h*ng/mg 84 123 280 AUCInf h*ng/mL 92 149 289 Pharmacokinetics in mice
[0164] B-1 was administered to male CD-1 mice (4-6 weeks old, 20-30 grams, 3 animals each group) via intravenous (IV) bolus at 1 mg/kg and by oral gavage (PO) at 10 mg/kg. C-1 was administered to 3 male CD-1 mice via oral gavage at 10 mg/kg. All animals had free access to food and water prior to dosing. Blood samples (-0.03 mL each time point) were collected via the jugular vein into tubes containing sodium heparin as the anticoagulant at 0.033, 0.083, 0.25, 0.5, 1, 2, 4, 8 and 24 hours post dose for IV
administration and 0.083, 0.25, 0.5, 1, 2, 4, 8 and 24 hours post dose for PO administration. The blood samples were then centrifuged for 5 minutes in a centrifuge refrigerated at 4 C. The resultant plasma samples were analyzed using LC/MS/MS to determine concentrations of B-1. Non-compartmental model with WinNonlin (Phoenix, version 8.0) software was used to calculate pharmacokinetic (PK) parameters. The PK results are listed in Table 5. The oral bioavailability of B-1 following oral gavage administration of B-1 in mice is 35%; and the oral bioavailability of B-1 following oral gavage administration of the prodrug C-1 is 55%.
Table 5. PK parameters in male CD-1 mice Unit IV lmg/kg PO 10mg/kg PO 10mg/kg n=3 n=3 n=3 T1/2 h 4.1 3.4 3.2 Tmaxh 5.3 1.7 Cmax ng/mL 165 330 AUCiast h*ng/mg 601 2129 2834 AUCInf h*ng/mL 608 2147 2851 Pharmacokinetics in monkeys
administration and 0.083, 0.25, 0.5, 1, 2, 4, 8 and 24 hours post dose for PO administration. The blood samples were then centrifuged for 5 minutes in a centrifuge refrigerated at 4 C. The resultant plasma samples were analyzed using LC/MS/MS to determine concentrations of B-1. Non-compartmental model with WinNonlin (Phoenix, version 8.0) software was used to calculate pharmacokinetic (PK) parameters. The PK results are listed in Table 5. The oral bioavailability of B-1 following oral gavage administration of B-1 in mice is 35%; and the oral bioavailability of B-1 following oral gavage administration of the prodrug C-1 is 55%.
Table 5. PK parameters in male CD-1 mice Unit IV lmg/kg PO 10mg/kg PO 10mg/kg n=3 n=3 n=3 T1/2 h 4.1 3.4 3.2 Tmaxh 5.3 1.7 Cmax ng/mL 165 330 AUCiast h*ng/mg 601 2129 2834 AUCInf h*ng/mL 608 2147 2851 Pharmacokinetics in monkeys
[0165] B-1 was administered to male cynomolgus monkeys (2-5 years old, 2-5 kg, animals each group) via intravenous (IV) bolus at 0.25 mg/kg and by oral gavage (PO) at 1 mg/kg; Animals in the IV group had free access to food and water (non-fasted) and animals in the PO group were fasted overnight prior to dosing (fasted). C-1 was administered to male cynomolgus monkeys (fasted or non-fasted, 3 each group) via oral gavage at 1 mg/kg. Blood samples (-0.5 mL each time point) were collected via the jugular vein into tubes containing potassium ethylenediaminetetraacetic acid (K2EDTA) as the anticoagulant at 0.033, 0.083, 0.25, 0.5, 1, 2, 4, 8 and 24 hours post dose for IV administration and 0.083, 0.25, 0.5, 1, 2, 4, 8 and 24 hours post dose for PO administration. The blood samples were then centrifuged for minutes in a centrifuge refrigerated at 2-8 C. The resultant plasma samples were analyzed using LC/MS/MS to determine concentrations of B-1. Non-compartmental model with WinNonlin (Phoenix, version 6.1) software was used to calculate pharmacokinetic (PK) parameters. The PK results are listed in Table 6. The oral bioavailability of B-1 following oral gavage administration of B-1 in monkeys is 27%. The oral bioavailability of B-1 following oral gavage administration of the prodrug C-1 is 57% and 53% at fasted and non-fasted conditions, respectively; and feeding condition did not impact oral absorption of C-1.
On the other hand, the oral bioavailability of baloxavir following administration of its prodrug baloxavir marboxil was largely affected by feeding conditions. The oral bioavailability of baloxavir was 10.5-11.5% and 50.6%, respectively, following oral administration of baloxavir marboxil to non-fasted and fasted monkeys (Baloxavir marboxil NDA document).
Table 6. PK parameters in cynomolgus monkeys B-1 B-1 PO lmg/kg Unit IV 0.25mg/kg PO lmg/kg n=3 n=3 n=3 Fasted Non-fasted t1/2 h 11 9.4 9.6 8.9 Tmaxh 3.3 2.0 2.0 Cmax ng/mL 267 52 54 AUCiasi h*ng/mg 204 231 414 400 AUChir h*ng/mL 257 274 503 469
On the other hand, the oral bioavailability of baloxavir following administration of its prodrug baloxavir marboxil was largely affected by feeding conditions. The oral bioavailability of baloxavir was 10.5-11.5% and 50.6%, respectively, following oral administration of baloxavir marboxil to non-fasted and fasted monkeys (Baloxavir marboxil NDA document).
Table 6. PK parameters in cynomolgus monkeys B-1 B-1 PO lmg/kg Unit IV 0.25mg/kg PO lmg/kg n=3 n=3 n=3 Fasted Non-fasted t1/2 h 11 9.4 9.6 8.9 Tmaxh 3.3 2.0 2.0 Cmax ng/mL 267 52 54 AUCiasi h*ng/mg 204 231 414 400 AUChir h*ng/mL 257 274 503 469
[0166] Incorporation of a selenium atom resulted in favorable pharmacokinetic and biological properties. Oral bioavailability of B-1 was 14% and 30%
respectively, following oral administration of B-1 and C-1 to rats. Oral bioavailability of B-1 and C-1 was 35% and 55% in CD-1 mice, respectively. Oral bioavailability of B-1 in monkeys was 27%
following oral administration of B-1. Oral bioavailability of B-1 following oral gavage administration of the prodrug C-1 to fasted and non-fasted monkeys was 57% and 53%
respectively; and feeding condition did not impact oral absorption of C-1. Furthermore, both B-1 and C-1 showed potent antivirus activity in influenza virus PR/8/34 mouse model as illustrated in Figure lA and Figure 1B.
Example 12
respectively, following oral administration of B-1 and C-1 to rats. Oral bioavailability of B-1 and C-1 was 35% and 55% in CD-1 mice, respectively. Oral bioavailability of B-1 in monkeys was 27%
following oral administration of B-1. Oral bioavailability of B-1 following oral gavage administration of the prodrug C-1 to fasted and non-fasted monkeys was 57% and 53%
respectively; and feeding condition did not impact oral absorption of C-1. Furthermore, both B-1 and C-1 showed potent antivirus activity in influenza virus PR/8/34 mouse model as illustrated in Figure lA and Figure 1B.
Example 12
[0167] A toxicity study of C-1 was conducted in Sprague Dawley (SD) rats. C-1 at 20, 100 and 500 mg/kg or vehicle (0.5% w/v CMC-Na and 0.1% v/v Tween-80 in DI water) was administered via oral gavage to Sprague Dawley rats (7-9 weeks, about 250-300 grams each for males and about 200-250 grams each for females) once daily for 7 days. 8 females and 8 males in each dose group were used. No C-1-related toxic findings (including abnormal clinical observation, alterations in body weight, change in food consumption and change in gross pathology) were observed at all the dose levels. C-1 was well tolerated and the maximum tolerated dose (MTD) was greater than 500 mg/kg/day in Sprague Dawley rats.
[0168] It is to be understood that the invention is not limited to the particular embodiments and aspects of the disclosure described above, as variations of the particular embodiments and aspects may be made and still fall within the scope of the appended claims. All documents cited to or relied upon herein are expressly incorporated by reference.
Claims (25)
1. A compound of Formula (I):
or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein:
each Ri is independently selected from the group consisting of H and halo;
each R2 is independently selected from the group consisting of H and halo;
R3 is selected from the group consisting of H, halo, Me, CN, and P(0)Me2;
each R4 is independently selected from the group consisting of Ci-C6 alkyl and cycloalkyl, wherein any two of R4 are optionally taken, together with the atoms to which they are attached, to form a C3-C6 cycloalkyl;
n and m are each independently 0, 1, 2, 3, or 4;
p is 0, 1, 2, or 3; and G is H or is selected from the group consisting of C(0)R, C(0)0R, C(0)NR'R, C(102-0-C(0)R, C(102-0-C(0)0R, and C(R')2-0-C(0)NR'R, wherein each R is selected from the group consisting of Ci-C6 alkyl, phenyl, pyridyl, cycloalkyl, and a 4-6 membered heterocyclic ring containing one or two heteroatoms selected from the group consisting of N, 0 and S as ring members, wherein the Ci-C6 alkyl, phenyl, pyridyl, C3-C6 cycloalkyl, and 4-6 membered heterocyclic ring of R are independently optionally substituted with one or two substituents selected from the group consisting of H, halo, CN, OH, NH2, Ci-C3 alkyl, phenyl, Ci-C4 alkoxy, Ci-C3 haloalkyl, and Ci-haloalkoxy; and each R' is independently selected from the group consisting of H and Ci-C3 alkyl.
or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein:
each Ri is independently selected from the group consisting of H and halo;
each R2 is independently selected from the group consisting of H and halo;
R3 is selected from the group consisting of H, halo, Me, CN, and P(0)Me2;
each R4 is independently selected from the group consisting of Ci-C6 alkyl and cycloalkyl, wherein any two of R4 are optionally taken, together with the atoms to which they are attached, to form a C3-C6 cycloalkyl;
n and m are each independently 0, 1, 2, 3, or 4;
p is 0, 1, 2, or 3; and G is H or is selected from the group consisting of C(0)R, C(0)0R, C(0)NR'R, C(102-0-C(0)R, C(102-0-C(0)0R, and C(R')2-0-C(0)NR'R, wherein each R is selected from the group consisting of Ci-C6 alkyl, phenyl, pyridyl, cycloalkyl, and a 4-6 membered heterocyclic ring containing one or two heteroatoms selected from the group consisting of N, 0 and S as ring members, wherein the Ci-C6 alkyl, phenyl, pyridyl, C3-C6 cycloalkyl, and 4-6 membered heterocyclic ring of R are independently optionally substituted with one or two substituents selected from the group consisting of H, halo, CN, OH, NH2, Ci-C3 alkyl, phenyl, Ci-C4 alkoxy, Ci-C3 haloalkyl, and Ci-haloalkoxy; and each R' is independently selected from the group consisting of H and Ci-C3 alkyl.
2. The compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein the compound is of Formula (I-1):
or a pharmaceutically acceptable salt, stereoisomer or solvate thereof
or a pharmaceutically acceptable salt, stereoisomer or solvate thereof
3. The compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein the compound is of Formula (1-2):
or a pharmaceutically acceptable salt, stereoisomer or solvate thereof
or a pharmaceutically acceptable salt, stereoisomer or solvate thereof
4. The compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein the compound is of Formula (1-3):
or a pharmaceutically acceptable salt, stereoisomer or solvate thereof
or a pharmaceutically acceptable salt, stereoisomer or solvate thereof
5. The compound of one any of claims 1-4, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein G is H.
6. The compound of one any of claims 1-4, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein G is selected from the group consisting of C(0)R, C(0)0R, C(0)NR'R, C(R')2-0-C(0)R, C(R')2-0-C(0)0R, and C(R')2-0-C(0)NR.
7. The compound of claim 6, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein G is selected from the group consisting of C(0)R, C(0)0R, C(102-0-C(0)R, and C(102-0-C(0)0R.
8. The compound of claim 7, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein G is selected from the group consisting of C(0)R, C(0)0R, CH2-0-C(0)R, and CH2-0-C(0)0R, where each R is independently C1-C6 alkyl, and the C1-C6 alkyl is optionally substituted with one group selected from H, halo, CN, OH, and NH2.
9. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein G is selected from the group consisting of:
10. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein R3 is selected from the group consisting of H, F, Cl, Br, Me, CN, and P(0)Me2.
11. The compound of claim 10, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein R3 is P(0)Me2.
12. The compound of claim 1, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein the compound is selected from the group consisting of:
12-(7,8-difluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,41oxazino[3,4-c1pyrido[2,1-f][1,2,41triazine-6,8-dione (A-1), 8-fluoro-6,11-dihydrodibenzo[b,e1selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,41oxazino[3,4-clpyrido[2,1-f][1,2,4]triazine-6,8-dione (A-2), 7-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,41oxazino[3,4-clpyrido[2,1-f][1,2,4]triazine-6,8-dione (A-3), 8,9-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,41oxazino[3,4-clpyrido[2,1-f][1,2,4]triazine-6,8-dione (A-4), 10-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-clpyrido[2,1-f][1,2,4]triazine-6,8-dione (A-5), 6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,41oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (A-6), 7,8,10-trifluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-3,4,12,12a-tetrahydro-1H-[1,41oxazino[3,4-c1pyrido[2,1-f][1,2,4]triazine-6,8-dione (A-7), 7,10-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H41,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (A-8), 9-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,41oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (A-9), (R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H41,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (B-1), (R)-12-((S)-8-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H41,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (B-2), (R)-12-((S)-7-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H41,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (B-3), (R)-12-((S)-8,9-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H41,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (B-4), (R)-12-((S)-10-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H41,4]oxazino[3,4-c]pyrido[2,1-11[1,2,4]triazine-6,8-dione (B-5), (R)-12-((S)-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-11[1,2,4]triazine-6,8-dione (B-6), (R)-12-((S)-7,8,10-trifluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-3,4,12,12a-tetrahydro-1H41,4]oxazino[3,4-c]pyrido[2,1-11[1,2,4]triazine-6,8-dione (B-7), (R)-12-((S)-7,10-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H41,4]oxazino[3,4-c]pyrido[2,1-11[1,2,4]triazine-6,8-dione (B-8) (R)-12-((S)-9-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H41,4]oxazino[3,4-c]pyrido[2,1-11[1,2,4]triazine-6,8-dione (B-9), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,4]oxazino[3,4-c]pyrido[2,1-11[1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (C-1), (((R)-12-((S)-8-fluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,41oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (C-2), (((R)-12-((S)-7-fluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,41oxazino[3,4-c1pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (C-3), (((R)-12-((S)-8,9-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,41oxazino[3,4-c]pyrido[2,1-f][1,2,41triazin-7-yl)oxy)methyl methyl carbonate (C-4), (((R)-12-((S)-10-fluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (C-5), (((R)-12-((S)-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,41oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-y0oxy)methyl methyl carbonate (C-6), (((R)-6,8-dioxo-12-((S)-7,8,10-trifluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-y1)oxy)methyl methyl carbonate (C-7), (((R)-12-((S)-7,10-difluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,41oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (C-8), (((R)-12-((S)-9-fluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (C-9), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-y1)oxy)methyl ethyl carbonate (D-1), 1-(((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,41oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-yl)oxy)ethyl methyl carbonate (D-2), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-c]pyrido[2,1-f][1,2,41triazin-7-yl)oxy)methyl acetate (D-3), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,41oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl isopropyl carbonate (D-4), (R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-y1 acetate (D-5), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,41oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl (2-methoxyethyl) carbonate (D-6), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,41oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl L-valinate (D-7), 1-(((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,41oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-yl)oxy)ethyl L-valinate (D-8), and (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,41oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl L-leucinate (D-9), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof
12-(7,8-difluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,41oxazino[3,4-c1pyrido[2,1-f][1,2,41triazine-6,8-dione (A-1), 8-fluoro-6,11-dihydrodibenzo[b,e1selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,41oxazino[3,4-clpyrido[2,1-f][1,2,4]triazine-6,8-dione (A-2), 7-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,41oxazino[3,4-clpyrido[2,1-f][1,2,4]triazine-6,8-dione (A-3), 8,9-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,41oxazino[3,4-clpyrido[2,1-f][1,2,4]triazine-6,8-dione (A-4), 10-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-clpyrido[2,1-f][1,2,4]triazine-6,8-dione (A-5), 6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,41oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (A-6), 7,8,10-trifluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-3,4,12,12a-tetrahydro-1H-[1,41oxazino[3,4-c1pyrido[2,1-f][1,2,4]triazine-6,8-dione (A-7), 7,10-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H41,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (A-8), 9-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,41oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (A-9), (R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H41,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (B-1), (R)-12-((S)-8-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H41,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (B-2), (R)-12-((S)-7-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H41,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (B-3), (R)-12-((S)-8,9-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H41,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (B-4), (R)-12-((S)-10-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H41,4]oxazino[3,4-c]pyrido[2,1-11[1,2,4]triazine-6,8-dione (B-5), (R)-12-((S)-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-11[1,2,4]triazine-6,8-dione (B-6), (R)-12-((S)-7,8,10-trifluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-3,4,12,12a-tetrahydro-1H41,4]oxazino[3,4-c]pyrido[2,1-11[1,2,4]triazine-6,8-dione (B-7), (R)-12-((S)-7,10-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H41,4]oxazino[3,4-c]pyrido[2,1-11[1,2,4]triazine-6,8-dione (B-8) (R)-12-((S)-9-fluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H41,4]oxazino[3,4-c]pyrido[2,1-11[1,2,4]triazine-6,8-dione (B-9), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,4]oxazino[3,4-c]pyrido[2,1-11[1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (C-1), (((R)-12-((S)-8-fluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,41oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (C-2), (((R)-12-((S)-7-fluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,41oxazino[3,4-c1pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (C-3), (((R)-12-((S)-8,9-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,41oxazino[3,4-c]pyrido[2,1-f][1,2,41triazin-7-yl)oxy)methyl methyl carbonate (C-4), (((R)-12-((S)-10-fluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (C-5), (((R)-12-((S)-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,41oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-y0oxy)methyl methyl carbonate (C-6), (((R)-6,8-dioxo-12-((S)-7,8,10-trifluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-y1)oxy)methyl methyl carbonate (C-7), (((R)-12-((S)-7,10-difluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,41oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (C-8), (((R)-12-((S)-9-fluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl methyl carbonate (C-9), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-y1)oxy)methyl ethyl carbonate (D-1), 1-(((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,41oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-yl)oxy)ethyl methyl carbonate (D-2), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-c]pyrido[2,1-f][1,2,41triazin-7-yl)oxy)methyl acetate (D-3), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,41oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl isopropyl carbonate (D-4), (R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-y1 acetate (D-5), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,41oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl (2-methoxyethyl) carbonate (D-6), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,41oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl L-valinate (D-7), 1-(((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elselenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,41oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-yl)oxy)ethyl L-valinate (D-8), and (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]selenepin-11-y1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,41oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl L-leucinate (D-9), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof
13. A compound of Formula (II), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein:
each Ri is independently selected from the group consisting of H and halo;
each R2is independently selected from the group consisting of H and halo;
R3is P(0)Me2 or P(0)Et2;
each R4 is independently selected from the group consisting of C1-C6 alkyl and cycloalkyl, wherein any two of R4 are optionally taken, together with the atoms to which they are attached, to form a C3-C6 cycloalkyl;
n and m are each independently 0, 1, 2, 3, or 4;
p is 0, 1, 2, or 3; and G is H or is selected from the group consisting of C(0)R, C(0)0R, C(0)NR'R, C(102-0-C(0)R, C(102-0-C(0)0R, and C(R')2-0-C(0)NR'R, wherein each R is selected from the group consisting of C1-C6 alkyl, phenyl, pyridyl, cycloalkyl, and a 4-6 membered heterocyclic ring containing one or two heteroatoms selected from the group consisting of N, 0 and S as ring members, wherein the C1-C6 alkyl, phenyl, pyridyl, C3-C6 cycloalkyl, and 4-6 membered heterocyclic ring of R are independently optionally substituted with one or two substituents selected from the group consisting of H, halo, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-haloalkoxy; and each R' is independently selected from the group consisting of H and C1-C3 alkyl.
each Ri is independently selected from the group consisting of H and halo;
each R2is independently selected from the group consisting of H and halo;
R3is P(0)Me2 or P(0)Et2;
each R4 is independently selected from the group consisting of C1-C6 alkyl and cycloalkyl, wherein any two of R4 are optionally taken, together with the atoms to which they are attached, to form a C3-C6 cycloalkyl;
n and m are each independently 0, 1, 2, 3, or 4;
p is 0, 1, 2, or 3; and G is H or is selected from the group consisting of C(0)R, C(0)0R, C(0)NR'R, C(102-0-C(0)R, C(102-0-C(0)0R, and C(R')2-0-C(0)NR'R, wherein each R is selected from the group consisting of C1-C6 alkyl, phenyl, pyridyl, cycloalkyl, and a 4-6 membered heterocyclic ring containing one or two heteroatoms selected from the group consisting of N, 0 and S as ring members, wherein the C1-C6 alkyl, phenyl, pyridyl, C3-C6 cycloalkyl, and 4-6 membered heterocyclic ring of R are independently optionally substituted with one or two substituents selected from the group consisting of H, halo, CN, OH, NH2, C1-C3 alkyl, phenyl, C1-C4 alkoxy, C1-C3 haloalkyl, and C1-haloalkoxy; and each R' is independently selected from the group consisting of H and C1-C3 alkyl.
14. The compound of claim 13, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein the compound is of Formula (II-3), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof
15. The compound of claim 13 or 14, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein G is H.
16. The compound of claim 13 or 14, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein G is selected from the group consisting of C(0)R, C(0)0R, C(0)NR'R, C(R)2-0-C(0)R, C(R')2-0-C(0)0R, and C(R)2-0-C(0)NR.
17. The compound of claim 16, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein G is selected from the group consisting of C(0)R, C(0)0R, C(102-0-C(0)R, and C(102-0-C(0)0R.
18. The compound of claim 17, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein G is selected from the group consisting of C(0)R, C(0)0R, CH2-0-C(0)R, and CH2-0-C(0)0R, where each R is independently C1-C6 alkyl, and the C1-C6 alkyl is optionally substituted with one group selected from H, halo, CN, OH, and NH2.
19. The compound of any one of claims 13, 14 and 16-18, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein G is selected from the group consisting of:
20. The compound of any one of claims 13-19, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein R3 is P(0)Me2.
21. The compound of claim 13, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, wherein the compound is selected from the group consisting of:
(R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-clpyrido[2,1-f][1,2,4]triazine-6,8-dione (E-1), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,4]oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-y0oxy)methyl ethyl carbonate (E-2), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,4]oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-y0oxy)methyl methyl carbonate (E-3), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,4]oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-y0oxy)methyl acetate (E-4), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,4]oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-y0oxy)methyl isopropyl carbonate (E-5), (R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,4]oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-y1 acetate (E-6), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-c]pyrido[2,1-f][1,2,41triazin-7-yl)oxy)methyl (2-methoxyethyl) carbonate (E-7), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,41oxazino[3,4-c]pyrido[2,1-f][1,2,41triazin-7-y0oxy)methyl L-valinate (E-8), 1-(((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-c1pyrido[2,1-f][1,2,41triazin-7-y0oxy)ethyl L-valinate (E-9), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-c]pyrido[2,1-f][1,2,41triazin-7-y0oxy)methyl L-leucinate (E-10), and (R)-9-(diethylphosphory1)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e1thiepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,41oxazino[3,4-clpyrido[2,1-f][1,2,41triazine-6,8-dione (F-1), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof
(R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-clpyrido[2,1-f][1,2,4]triazine-6,8-dione (E-1), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,4]oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-y0oxy)methyl ethyl carbonate (E-2), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,4]oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-y0oxy)methyl methyl carbonate (E-3), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,4]oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-y0oxy)methyl acetate (E-4), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,4]oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-y0oxy)methyl isopropyl carbonate (E-5), (R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,4]oxazino[3,4-clpyrido[2,1-f][1,2,4]triazin-7-y1 acetate (E-6), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-c]pyrido[2,1-f][1,2,41triazin-7-yl)oxy)methyl (2-methoxyethyl) carbonate (E-7), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,41oxazino[3,4-c]pyrido[2,1-f][1,2,41triazin-7-y0oxy)methyl L-valinate (E-8), 1-(((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-c1pyrido[2,1-f][1,2,41triazin-7-y0oxy)ethyl L-valinate (E-9), (((R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,elthiepin-11-y1)-9-(dimethylphosphory1)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H41,41oxazino[3,4-c]pyrido[2,1-f][1,2,41triazin-7-y0oxy)methyl L-leucinate (E-10), and (R)-9-(diethylphosphory1)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e1thiepin-11-y1)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,41oxazino[3,4-clpyrido[2,1-f][1,2,41triazine-6,8-dione (F-1), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof
22. A pharmaceutical composition comprising a compound of any one of claims 1-21, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, and one or more pharmaceutically acceptable carriers.
23. A method of treating influenza, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of claims 1-21, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, or a pharmaceutical composition of claim 22.
24. A compound of any one of claims 1-21, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, or a pharmaceutical composition of claim 22 for use in treating influenza.
25. Use of a compound of any one of claims 1-21, or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, or a pharmaceutical composition of claim 22 in the manufacture of a medicament for use in treating influenza.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962872998P | 2019-07-11 | 2019-07-11 | |
US62/872,998 | 2019-07-11 | ||
US201962944309P | 2019-12-05 | 2019-12-05 | |
US62/944,309 | 2019-12-05 | ||
PCT/US2020/041578 WO2021007506A1 (en) | 2019-07-11 | 2020-07-10 | Compounds useful to treat influenza virus infections |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3142030A1 true CA3142030A1 (en) | 2021-01-14 |
Family
ID=74115271
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3142030A Pending CA3142030A1 (en) | 2019-07-11 | 2020-07-10 | Compounds useful to treat influenza virus infections |
Country Status (11)
Country | Link |
---|---|
US (2) | US20220033416A1 (en) |
EP (1) | EP3996716A4 (en) |
JP (1) | JP2022541404A (en) |
KR (1) | KR20220034827A (en) |
CN (2) | CN114907378A (en) |
AU (1) | AU2020310921A1 (en) |
BR (1) | BR112022000503A2 (en) |
CA (1) | CA3142030A1 (en) |
IL (1) | IL289655A (en) |
MX (1) | MX2022000453A (en) |
WO (1) | WO2021007506A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2022000453A (en) | 2019-07-11 | 2022-04-18 | Nanjing Zhengxiang Pharmaceuticals Co Ltd | Compounds useful to treat influenza virus infections. |
AU2022205484A1 (en) * | 2021-01-08 | 2023-08-24 | Medshine Discovery Inc. | Pyridone multiple-membered ring derivatives and use thereof |
TW202308646A (en) * | 2021-05-10 | 2023-03-01 | 大陸商南京征祥醫藥有限公司 | Crystal form of a compound for treating influenza and use thereof |
CN114790214B (en) * | 2021-06-11 | 2024-01-26 | 南京征祥医药有限公司 | Selenium-containing anti-influenza compound and preparation method of intermediate pyridotriazine dione derivative and dihydrodibenzoseleno-flat derivative thereof |
CN117924284A (en) * | 2021-11-01 | 2024-04-26 | 南京知和医药科技有限公司 | High-efficiency antiviral compound and application thereof |
CN115947737B (en) * | 2022-01-26 | 2023-11-28 | 南京赛弗斯医药科技有限公司 | Selenium-containing compound and application thereof |
CN118047795A (en) * | 2022-03-09 | 2024-05-17 | 南京征祥医药有限公司 | Preparation method of selenium-containing anti-influenza medicine |
WO2024007997A1 (en) * | 2022-07-05 | 2024-01-11 | 辉诺生物医药科技(杭州)有限公司 | Crystal form of pyridone polycyclic derivative and preparation method therefor |
CN118239980A (en) * | 2022-10-08 | 2024-06-25 | 石家庄迪斯凯威医药科技有限公司 | Anti-influenza virus derivative and application thereof |
CN117924325A (en) * | 2022-11-09 | 2024-04-26 | 石家庄迪斯凯威医药科技有限公司 | Anti-influenza virus derivative and application thereof |
WO2024098273A1 (en) * | 2022-11-09 | 2024-05-16 | 石家庄迪斯凯威医药科技有限公司 | Anti-influenza virus phosphate ester compound and use thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5971830B1 (en) | 2015-04-28 | 2016-08-17 | 塩野義製薬株式会社 | Substituted polycyclic pyridone derivatives and prodrugs thereof |
RU2712275C9 (en) | 2015-04-28 | 2020-03-19 | Сионоги Энд Ко., Лтд. | Substituted polycyclic pyridone derivatives and prodrugs thereof |
CR20180356A (en) * | 2015-12-15 | 2018-08-22 | Shionogi & Co | A MEDICINAL CHARACTERIZED FOR COMBINING AN INHIBITOR OF THE CAP-DEPENDENT ENDONUCLEASE OF THE INFLUENZA VIRUS AND AN ANTI-INFLUENZA DRUG |
CR20190123A (en) * | 2016-08-10 | 2019-04-30 | Shionogi & Co | Substituted polycyclic pyridone derivative and pharmaceutical composition containing prodrug thereof |
WO2019052565A1 (en) * | 2017-09-18 | 2019-03-21 | 广东东阳光药业有限公司 | Influenza virus replication inhibitor and use thereof |
CN109503625A (en) | 2018-01-19 | 2019-03-22 | 赵蕾 | A kind of polycyclic pyridines ketone compound and its pharmaceutical composition and purposes |
MX2022000453A (en) | 2019-07-11 | 2022-04-18 | Nanjing Zhengxiang Pharmaceuticals Co Ltd | Compounds useful to treat influenza virus infections. |
-
2020
- 2020-07-10 MX MX2022000453A patent/MX2022000453A/en unknown
- 2020-07-10 CN CN202210528727.1A patent/CN114907378A/en active Pending
- 2020-07-10 AU AU2020310921A patent/AU2020310921A1/en active Pending
- 2020-07-10 WO PCT/US2020/041578 patent/WO2021007506A1/en unknown
- 2020-07-10 EP EP20836808.4A patent/EP3996716A4/en active Pending
- 2020-07-10 KR KR1020227004191A patent/KR20220034827A/en unknown
- 2020-07-10 CN CN202080004760.3A patent/CN113226327B/en active Active
- 2020-07-10 CA CA3142030A patent/CA3142030A1/en active Pending
- 2020-07-10 JP JP2022500920A patent/JP2022541404A/en active Pending
- 2020-07-10 US US17/297,407 patent/US20220033416A1/en not_active Abandoned
- 2020-07-10 BR BR112022000503A patent/BR112022000503A2/en unknown
-
2022
- 2022-01-05 US US17/569,367 patent/US11466029B2/en active Active
- 2022-01-06 IL IL289655A patent/IL289655A/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2022000453A (en) | 2022-04-18 |
KR20220034827A (en) | 2022-03-18 |
US20220033416A1 (en) | 2022-02-03 |
US11466029B2 (en) | 2022-10-11 |
EP3996716A1 (en) | 2022-05-18 |
US20220127282A1 (en) | 2022-04-28 |
WO2021007506A1 (en) | 2021-01-14 |
AU2020310921A1 (en) | 2022-02-10 |
TW202118763A (en) | 2021-05-16 |
IL289655A (en) | 2022-03-01 |
EP3996716A4 (en) | 2023-07-26 |
CN114907378A (en) | 2022-08-16 |
BR112022000503A2 (en) | 2022-06-07 |
CN113226327B (en) | 2022-05-17 |
JP2022541404A (en) | 2022-09-26 |
CN113226327A (en) | 2021-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3142030A1 (en) | Compounds useful to treat influenza virus infections | |
CN115135320B (en) | Specific tryptamine for the treatment of mood disorders | |
ES2605625T3 (en) | P2Y12 receptor cyclopropyl modulators | |
EP2686320B1 (en) | Tricyclic gyrase inhibitors | |
ES2974494T3 (en) | Pyridazinone-Fused Tricyclic Compounds Useful for Treating Orthomyxovirus Infections | |
TWI654171B (en) | Carotenoid derivatives, their pharmacologically acceptable salts, or their pharmacologically acceptable esters or amidines | |
EA024681B1 (en) | Imidazopyridines as respiratory syncytial virus antiviral agents | |
US9428458B2 (en) | Substituted pyridoxine-lactam carboxylate-salts | |
US20110223131A1 (en) | Antiviral compounds | |
RU2489422C1 (en) | Fluorine-substituted (3r,4r,5s)-5-guanidino-4-acylamino-3-(pentan-3-yloxy)cyclohexene-1-carboxylic acids, esters thereof and method of application | |
EP2016081B1 (en) | Anti-viral pyrimidine nucleoside derivatives | |
TWI841759B (en) | Compounds useful to treat influenza virus infections | |
US20230322735A1 (en) | Azetidinyl tryptamines and methods of treating psychiatric disorders | |
PL184861B1 (en) | Improvement in tolerance of pharmaceutically active beta-amino acids | |
EA047104B1 (en) | COMPOUNDS SUITABLE FOR TREATING INFLUENZA VIRUS INFECTIONS | |
CN116284133B (en) | Novel six-membered heterocyclic derivative, and pharmaceutical composition and application thereof | |
US7253177B2 (en) | Synthesis and antimalarial activity of pyrrolo[3,2-f]quinazoline-1,3-diamine derivatives | |
WO2017040459A1 (en) | Improved solubility for target compounds | |
WO2018203564A1 (en) | Liphagal analog and multi-targeted kinase inhibitor containing liphagal or analog thereof | |
RU2520836C1 (en) | (3r,4r,5s)-4-amino-5-(2,2-difluoroacetylamino)-3-(1-ethylpropoxy)-cyclohex-1-enecarboxylic acid and its ethers, method of obtaining and applying thereof | |
FR3025200A1 (en) | MACROCYCLIC POLYETHERS N-ARYL-TRICYCLOPYRIMIDINE-2-AMINE DERIVATIVES | |
US20230061859A1 (en) | Pyrido[2,3-d]pyrimidine hiv-1 reverse transcriptase inhibitor wb3, preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20240617 |